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Summary
Several hurdles have to be overcome in the process of determining the three-dimensional struc-
ture of a biomacromolecule. In many cases extensive protein engineering is necessary in order
to produce large amounts of material that can be purified to homogeneity. The protein of in-
terest needs to be in its native state, stable and monodisperse. To obtain an atomic model by
X-ray diffraction, the generation of well-diffracting crystals is the next bottleneck. Structures
of integral membrane proteins are of particular interest because they are the site of action for
the majority of drugs. Although amazing accomplishments have been made in the last decade,
membrane protein targets remain particularly challenging candidates. This thesis consists of
three parts describing advances at various steps of the procedure for eukaryotic and prokaryotic
transport proteins from different families.
Health problems related to obeisity, unfavourable blood cholesterol levels and diabetes have
become a major concern in the industrialized world. Bile acid homeostasis, being tightly con-
nected to cholesterol levels and the regulation of glucose and lipid metabolism, is thereby of
high medical relevance. The sodium taurocholate cotransporting polypeptide NTCP/Ntcp is a
key player in the enterohepatic bile salt circulation as it represents the major uptake system for
conjugated bile salts into hepatocytes. According to the nomenclature introduced by the Human
Genome Organization (HUGO), NTCP/Ntcp is a member of the solute carrier 10 (Slc10) family.
The first part of the thesis describes the functional expression of rat Ntcp using baculovirus-
infected insect cells. Small-scale purification allowed us to estimate yield and quality of the
protein and measures to obtain higher amounts of protein are discussed.
Organic anion transporting polypeptides (OATPs/Oatps), which form the solute carrier 21
(Slc21) superfamily, are also capable of bile acid uptake as part of the enterohepatic bile salt
circulation. However, due to their important role in drug disposition, they are mainly studied in
the context of drug-transporter or drug-drug interactions. Structural information would greatly
advance these investigations. One characteristic structural feature of OATPs/Oatps is a large
extracellular loop of about 100 amino acids length. This highly conserved, cysteine-rich loop
was predicted to fold into a Kazal-type domain. We therefore designed several constructs for the
soluble expression of the proposed domain. While we were able to produce sufficient amounts
of pure material, the fragment did not fold into a defined structure. Since the major issue seemed
to be the incorrect formation of disulfide bonds, we focused on providing an appropriate redox
environment to allow the domain to fold into its native conformation. The biophysical charac-
terization of the extracellular loop of Oatp1a4 is described in chapter 3.
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Chapter 4 is concerned with a different kind of bile salt transporter. The multidrug ef-
flux pump AcrB from Escherichia coli belongs to the resistance/nodulation/cell division (RND)
family and resides in the inner membrane of gram-negative bacteria. As part of a multiprotein
complex, it confers resistance to a large number of noxious compounds, including antibiotics,
dyes and detergents such as bile salts. Pathogens acquiring resistance to antibiotics are a threat
to human health, and the structure and function of this transporter have been investigated exten-
sively.
In our study, AcrB served as a model protein for the use of designed ankyrin repeat pro-
teins (DARPins) to improve the quality of membrane protein crystals. In chapter 4 of this
thesis we present a detailed analysis of the interaction of DARPin binders with AcrB. Inter-
estingly, DARPins from the third and fourth round of ribosome display selection were found to
bind to their target on a single, overlapping site. In comparing the crystal structures of three
AcrB-DARPin complexes, we find that small differences in the binding geometry of seemingly
redundant binders significantly affect the crystal packing. This observation advances our under-
standing of the engineering of crystal contacts. The structures also allow us to learn about the
plasticity of a synthetic binding interface. Furthermore, we present a detailed biophysical analy-
sis of the interaction of nine DARPin binders with AcrB. Small variations in the binding surface
of the DARPins can cause differences in the affinity and stoichiometry of complex formation
and the specificity for binding to AcrB.
vZusammenfassung
Die erfolgreiche Strukturbestimmung eines biologischen Makromoleküls erfolgt in mehreren
Schritten, die den Forscher vor Schwierigkeiten stellen können. In vielen Fällen müssen zunächst
Eigenschaften des Zielproteins wie Löslichkeit und Stabilität durch Modifikation der Sequenz
verbessert werden, um genügend Material produzieren und reinigen zu können. Große Mengen
einer möglichst homogenen Proteinlösung, in der das Molekül stabil in seiner nativen Form vor-
liegt, werden für die Strukturbestimmung benötigt. Eine weitere Schwierigkeit ist die Bildung
eines Kristalls mit guten Streueigenschaften für die Röntgenstrukturanalyse, der die Messung
der Daten erlaubt, aus denen ein Modell bei ausreichender Auflösung berechnet werden kann.
Die meisten Medikamente wirken durch die Interaktion mit integralen Membranproteinen,
die auf der Zelloberfläche zugänglich sind. Daher sind dreidimensionale Strukturen dieser Pro-
teinklasse von besonderem Interesse. Trotz großer Fortschritte in diesem Bereich im letzten
Jahrzehnt bleiben Membranproteine eine besondere Herausforderung. Diese Arbeit besteht aus
drei Teilen, die Projekte auf verschiedenen Ebenen der Strukturbestimmung beschreiben. Die
Zielproteine gehören zu unterschiedlichen Familien eukaryotischer und prokaryotischer Mem-
brantransporter.
In der postindustriellen Gesellschaft der westlichen Welt spielen Gesundheitsrisiken in-
folge von Übergewicht, hohem Cholesterinspiegel oder Diabetes eine immer größere Rolle.
Die Gallensalzhomöostase hat direkten Einfluss auf Cholesterinspiegel und die Regulation des
Kohlenhydrat- und Fettstoffwechsels und ist in diesem Zusammenhang von hoher medizini-
scher Bedeutung. Ein wichtiger Bestandteil des Leber-Darm-Kreislaufs der Gallensäuren ist der
Natrium/Taurocholat-Kotransporter NTCP/Ntcp. Dieses Transportprotein gehört zur Familie der
natriumabhängigen Gallensalztransporter (Solute carrier 10 family, Slc10) und stellt den wich-
tigsten Aufnahmeweg für konjugierte Gallensäuren in die Leber dar. Der erste Teil dieser Arbeit
befasst sich mit der funktionellen Expression von Ntcp aus der Rattenleber mit Hilfe von bacu-
lovirusinfizierten Insektenzellen. Zur Quantifizierung der Proteinmenge wurde auch ein erster
Reinigungsversuch im kleinen Maßstab unternommen.
Mitglieder der Organo-Anion-Transporter Proteinfamilie (englisch: organic anion transpor-
ting polypeptides, OATPs/Oatps; auch solute carrier 21, Slc21) spielen eine untergeordnete Rol-
le bei der Aufnahme von Gallensäuren beispielsweise in Leberzellen. Ungleich wichtiger ist je-
doch ihr Beitrag zur Entgiftung durch Aufnahme von Fremdstoffen in Leber oder Niere. Da auch
die Halbwertszeit von Medikamenten von dem Transport durch OATPs/Oatps abhängt, werden
Wechselwirkungen zwischen Substanzen und dem entsprechenden Transportprotein oder auch
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der Einfluss eines Medikaments auf den Transport eines anderen Wirkstoffs intensiv untersucht.
Diese Studien könnten stark von Proteinstrukturen profitieren, die die Modellierung potentieller
Interaktionen ermöglichen würden. Ein charakteristisches Merkmal von OATPs/Oatps ist eine
extrazelluläre Domäne zwischen zwei Transmembranhelices, die aus etwa 100 Aminosäuren
besteht. Diese Domäne, für die eine Struktur ähnlich der Kazal Serinproteaseinhibitoren pos-
tuliert wurde, beinhaltet zehn hochkonservierte Cysteinreste. Kapitel 3 dieser Arbeit beschreibt
die Produktion mehrerer Fragmente von Oatp1a4 auf der Grundlage der vorgeschlagenen Struk-
tur mit dem Ziel der Herstellung einer löslichen Domäne. Obwohl genügend Protein hergestellt
und zufriedenstellend gereinigt werden konnte, stellte sich heraus, dass das Fragment nicht in der
gewünschten Domänenstruktur, sondern in einer ungefalteten Form vorlag. Da die Hauptschwie-
rigkeit in der korrekten Ausbildung der Disulfidbrücken lag, konzentriert sich diese Arbeit auf
die Optimierung einer geeigneten Redoxbedingung, die die Faltung des Proteins in die native
Konformation ermöglicht. Kapitel 3 beschreibt ausführlich die Analyse des extrazellulären Teils
von Oatp1a4 aus der Rattenleber mit Hilfe biophysikalischer Methoden.
Kapitel 4 widmet sich einem andersartigen Gallensalztransporter, nämlich dem Transporter
AcrB aus Escherichia coli. Dieses Protein gehört zu der Familie von RND Transportern (re-
sistence/nodulation/cell division - Resistenz/Knöllchenbildung/Zellteilung), deren Mitglieder in
der inneren Membran gramnegativer Bakterien zu finden sind. In Form eines Proteinkomplexes
schützt AcrB die Zelle vor einer Vielzahl schädlicher Substanzen, wie zum Beispiel Antibiotika,
Farbstoffe oder Detergentien, indem es diese aus dem Zellinneren ausschleust.
Dieser Teil der Doktorarbeit befasst sich mit der Kristallisation von Membranproteinen un-
ter Zuhilfenahme von Bindungsproteinen, die aus Ankyrinmodulen aufgebaut sind (designed
ankyrin repeat proteins, DARPins), zur Verbesserung der Streueigenschaften der Kristalle. AcrB
diente uns hierfür als Modellsystem. Die Untersuchung der DARPin Proteine, die durch Evo-
lution im Reagenzglas für die spezifische Bindung an AcrB selektiert wurden, ergab, dass die
meisten Binder mit dem selben Teil der Oberfläche des Transporters wechselwirken. Trotz die-
ser dominanten Bindungstelle macht der Vergleich dreier Kristallstrukturen von AcrB-DARPin
Komplexen deutlich, wie unterschiedlich sich ähnliche Bindungspartner auf die Packung und
Streueigenschaften des Kristalls auswirken können. Die Strukturen geben ausserdem Einblick
in die Variabilität des molekularen Aufbau einer synthetischen Bindungsoberfläche. Für insge-
samt neun Komplexe wurde zudem die Interaktion zwischen DARPin und AcrB mit Hilfe von
biophysikalischen Methoden untersucht. Auch hier wiesen ähnliche Bindungsmoleküle Unter-
schiede im Hinblick auf Affinität, Stöchiometrie und Spezifität der Wechselwirkung auf.
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Chapter 1
Introduction
1.1 Classification of membrane proteins
Cells and their organelles are surrounded by a lipid bilayer. Membrane proteins mediate the
interaction between the compartments, such as the cytoplasm and the extracellular space. This
includes signal transmission and the controlled exchange of polar substances that cannot cross
the barrier. Membrane proteins, accounting for roughly one third of the human proteome [1],
can be classified in various ways. One possibility is to distinguish between proteins with dif-
ferent secondary structure elements. Beta-barrel proteins such as porins are found in the outer
membrane of gram-negative bacteria and in cell organelles. Most integral membrane proteins
are alpha-helical. When grouped according to their function, they are roughly divided into re-
ceptors, enzymes, channels and transporters. Membrane proteins also play a structural role, act
as ligands or mediate vesicle fusion. The following section will focus on transporters, which are
the topic of this thesis.
Since the lipid bilayer forms a barrier for polar and charged molecules, their concentration on
either side can be substantially different. The physiological extracellular sodium concentration is
ten times greater than in the cytoplasm. Conversely, potassium is present at a low concentration
in the extracellular fluid, while the concentration in the cell is much higher. This chemical
potential, as well as other potentials such as the proton motive force, is used to store and provide
energy for biological processes.
Membrane channels and transporters mediate the flux of ions, the uptake of nutrients into
the cells, the extrusion of harmful compounds and the generation of concentration gradients
across the membrane. The mechanism depends on the direction of transport. Proteins that allow
1
2 CHAPTER 1. INTRODUCTION
1. Channels/Pores 2. Electrochemical 
potential-driven transporters
3. Primary active transporters 4. Group translocators
5. Transport electron carriers 8. Accessory factors
involved in transport
9. Incompletely characterized
transport systems
1.A. α-Type channels
1.B. β-Barrel porins
 1.B.17 The outer membrane  
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1.F. Vesicle fusion pores
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2.A. Porters
 2.A.1 The Major Facilitator  
           Superfamily (MFS)
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           nodulation-cell division  
           superfamily (RND)
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          (LctP) family
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          symporter (BASS)  
          family
 2.A.60 The organo anion  
           transporter (OAT)  
          family
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       porters
2.C. Ion-gradient-driven energizers
3.A P-P-bond-hydrolysis-driven  
 transporters
 3.A.1. The ATP-binding casset 
            te (ABC) superfamily
 3.A.2. The F-type ATPase  
            superfamily
 3.A.3 The P-type ATPase  
           superfamily
3.B. Decarboxylation-driven trans 
 porters
3.C. Methyltransfer-driven trans 
 porters
3.D. Oxidoreduction-driven trans 
 porters
3.E. Light absorption-driven trans 
 porters
4.A. Phosphotransfer-driven   
 group translocators
4.B. Nicotinamide ribonucleoside  
 uptake transporters
4.C. Acyl CoA ligase-coupled  
 transporters
5.A. Transmembrane 2-electron  
 transfer carriers
5.B. Transmembrane 1-electron  
 transfer carriers
8.A. Auxiliary transport proteins
8.B. Ribosomally synthesized  
 protein/peptide toxins that  
 target channels and carriers
8.C. Non-ribosomally synthesized  
 toxins that target channels and  
 carriers
9.A. Recognized transporters of  
 unknown biochemical mecha 
 nism
9.B. Putative transport proteins
9.C. Functionally characterized  
 transporters lacking identified  
 sequences
Figure 1.1: Classification of transporters and channels according to the TC system. Transporter
families that will be described in this thesis are marked in red.
diffusion along the concentration gradient are named facilitators or passive transporters. Simi-
larly, channels allow passive diffusion of water or a specific ion. In contrast to facilitators, they
are characterized by fast rates and a gating mechanism that controls the open probability of the
pore. Voltage-gated ion channels open at a certain membrane potential, whereas ligand-gated
ion channels conduct in response to ligand binding. Active transport occurs against the con-
centration gradient of the substrate and therefore requires energy. In the case of primary active
transport, the energy is provided by ATP hydrolysis. The Na+K+-ATPase is one of the proteins
that maintains the above mentioned ion gradients. A second class of proteins using energy from
ATP hydrolysis to move their substrate across the membrane barrier are ATP binding cassette
(ABC) transporters. Alternatively, the translocation of the substrate can be coupled to the co-
transport or antiport of a second molecule. In this process termed secondary active transport, the
energy is provided by the electrochemical gradient of protons or ions.
The human genome project and sequencing of other genomes has provided us with exten-
sive information that allowed the identification of numerous genes. The Gene Nomenclature
Committee of the Human Genome Organization (HUGO) grouped human transport proteins
into families of solute carriers (SLC) [2,3]. This classification system contains passive trans-
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porters and secondary active transporters, but not primary active transporters and ion or water
channels. The nomenclature is SLC followed by the number of the family, a letter referring to
the subfamily and a number for the individual transporter. Members of the same family share at
least 20 % sequence identity. An updated list contains 48 families and 368 transporter genes as
of 2010 (http://www.bioparadigms.org/slc/menu.asp). The nomenclature is extended to known
homologues of the human proteins. Non-human proteins are designated with lower-case let-
ters. The eukaryotic transporters described in this thesis are members of the sodium-bile salt
cotransport superfamily (SLC10/Slc10) and the organic anion transporter family (SLCO/SlcO
or SLC21/Slc21).
The Transport Classification (TC) system is an alternative way to group transport proteins
and channels (Figure 1.1, similar to the Enzyme Commission (EC) system [4]). A database
(Transport Classification Database, TCDB) is maintained online. This nomenclature described
in Figure 1.1 is not exclusively based on sequence alignments, but includes experimental infor-
mation. It applies to all transporters and channels from eukaryotic or prokaryotic origin. Slc10
family members are assigned to the bile acid:Na+ symporter family, while Slc21 proteins are
grouped in the organic anion transporter family together with some members of the Slc22 fam-
ily. The multidrug efflux pump AcrB described in chapter 4 belongs to the family of resistance-
nodulation transporters. All membrane proteins studied in this thesis are electrochemical-potential-
driven transporters.
1.2 Advances of Membrane Protein Structural Biology
In 1985, the first high-resolution structure of a membrane protein was solved by X-ray crys-
tallography [5]. The structure of the photosynthetic reaction center from Rhodopseudomonas
viridis proved that in principle, membrane proteins are amenable to structure determination.
In 1988, Johann Deisenhofer, Robert Huber and Hartmut Michel received the Nobel price in
Chemistry for this accomplishment. Even though membrane proteins are still underrepresented
in the Protein Data Bank (PDB), accounting for 10 % of all structures, the number of membrane
protein structures is steadily increasing and has reached 241 unique structures as of 2010 [6].
The progress is due to advances at all stages of the structure determination process. Methods
have been developed on the level of target selection, overexpression and crystallization. In the
following I will highlight those relevant to this thesis and illustrate them with examples.
4 CHAPTER 1. INTRODUCTION
1.2.1 Expression strategies
High-resolution structure determination by X-ray crystallography or NMR requires a large quan-
tity of protein in the range of milligrams. The first membrane proteins studied were isolated from
tissues where they are abundant in high amounts. Examples are the light-driven proton pump
bacteriorhodopsin, which can be purified from the purple membranes of halobacteria. In these
membranes, bacteriorhodopsin is present at high concentration in a two-dimensional crystalline
arrangement. Rhodopsin is a similar case. The G-protein coupled receptor (GPCR) was isolated
from bovine retina. Despite the high relevance of structural information on GPCRs for drug de-
sign, rhodopsin was the only receptor that could be isolated in high amounts, making it amenable
to structure determination. It is not only due to the progress in protein production, but also the
design of more stable variants of the protein and advances in crystallization technology, that
high-resolution structures of the human GPCRs β2-adrenergic receptor [7] and A2A adenosine
receptor [8] are now available.
Target selection
Highly homologous membrane proteins can behave very differently when produced in a partic-
ular expression system. One approach to find a candidate for structure determination is genome
pooling. A large number of homologous proteins from different organisms are screened for
overexpression. The progress in sequencing of genomes has increased the number of potential
targets. If available, bacterial homologs are preferred candidates as they can be more likely pro-
duced in a prokaryotic expression system. In particular proteins from thermophilic organisms
promise higher stability. Examples for the successful structure determination of a bacterial ho-
molog are the first structures of ABC transporters BtuCD from Escherichia coli [9] or Sav1866
from Staphylococcus aureus [10].
Expression systems
Advances have been made in the overexpression of recombinant membrane proteins. Bacterial
expression systems are preferred because they are cheap and easy to handle. However, since
membrane proteins are only stable once they have integrated into the lipid bilayer, overproduc-
tion of membrane proteins is often toxic to the expression host and can lead to the formation
of intracellular inclusion bodies. Escherichia coli strains C41(DE3) and C43(DE3) have been
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selected for their ability to tolerate membrane protein overproduction [11]. Presumably, these
strains can accomodate a larger amount of protein in their membranes.
Eukaryotic expression systems have been used successfully in many cases. Yeast, being
the simplest eukaryotic system with well-characterized genetics, has been widely used. The X-
ray structure of murine P-glycoprotein was solved recently using protein purified from Pichia
pastoris for crystallization [12]. The structure is a major accomplishment representing the first
structure of a mammalian ABC-transporter. P-glycoprotein, also referred to as multidrug resis-
tance protein 1 (MDR1), is of clinical importance because it limits the bioavailability of drugs.
Amongst other substrates, chemotherapeutics are exported out of cells.
Insect cells or mammalian cell lines represent a more complex eukaryotic expression system.
One can assume that both the biosynthesis of membrane proteins and the composition of the lipid
bilayer are more similar and therefore more suitable for the expression of eukaryotic membrane
proteins. Also, these expression systems yield proteins with post-transcriptional modifications
such as glycosylation. In particular baculovirus-infected insect cells can yield high amounts of a
recombinant protein. Chapter 2 will describe the functional expression of a sodium taurocholate
cotransporter from rat liver in baculovirus-infected insect cells.
Engineering
In many cases, engineering of the target is necessary to obtain high expression levels and pro-
tein amenable to crystallization. The bottleneck of membrane protein expression is the correct
insertion into the membrane. When the N-terminus of the target is located extracellularly, fusion
of the terminus to a periplasmic protein such as maltose binding protein (MBP) or thioredoxin
has helped integration of the polypeptide chain into the membrane. By this means, GPCR con-
structs have been identified which can be expressed in E. coli even though this protein family is
exclusively found in eukaryotes [13].
Like their soluble counterparts, many membrane proteins contain flexible regions that impair
stability of the isolated molecule and prevent crystallization. Trimming of the termini or short-
ening of loops is often necessary. Crystallization of β2-adrenergic receptor critically depended
on engineering of a more rigid construct. In addition to the truncation of the long C-terminus,
the dynamic protein was stabilized by replacing a flexible loop with T4 lysozyme [14].
If the protein of interest contains soluble domains, it might be worthwhile to investigate their
properties. The nucleotide binding domains of ABC transporters can usually be expressed sol-
ubly. X-ray structures of those proteins have provided insight in how the transport is energized.
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Similarly, structures of regulatory domains of ion channels have been solved. One example is the
PAS domain of hERG [15], a human potassium channel expressed in heart and brain. In chapter
3, the expression of an extracellular domain of organic anion transporter Oatp1a4 is described.
1.2.2 Solubilization and purification
Prior to purification, membrane proteins need to be separated from the lipid bilayer using de-
tergent. The choice of the detergent is critical for the integrity of the membrane protein. While
a more powerful detergent might be able to extract more material, it can also interfere with
the interactions between the transmembrane segments and thereby disrupt the native fold of the
protein. The best choice for solubilization may not be the same detergent the membrane protein
tolerates best during purification. For crystallization, yet another detergent may be optimal. This
additional parameter which is innate to membrane proteins makes it necessary to screen many
conditions for each construct. It is therefore important to optimize the efficiency of the screening
procedure, both to find a well-behaving construct and appropriate buffer conditions. A popular
approach is to fuse the C-terminus of the candidate to green fluorescent protein (GFP) [16], al-
lowing easy detection of expression, cellular location, solubilization and monodispersity of the
unpurified protein by fluorescent size exclusion chromatography [17].
1.2.3 Membrane Protein Crystallization
Lipidic cubic phase
Although crystallization by vapor diffusion has been successful in many cases, some membrane
proteins are not stable enough outside of the lipid bilayer. Lipids are necessary for the stability
of some membrane proteins. Including phospholipids in the crystallization drop improved or
was even required for crystallization in some cases [18,19]. For instance, a study on lactose per-
mease showed how progressive addition of Escherichia coli phospholipids during crystallization
lead to the formation of different crystal forms with greatly improved diffraction properties [20].
Landau and Rosenbusch demonstrated that membrane proteins can be reconstituted and crystal-
lized in a lipidic bilayer environment [21]. Monoolein spontaneously forms a three-dimensional
lipidic cupic phase when mixed with water. Membrane proteins reconstituted into this lipidic
bilayer can form crystals by dehydration which induces a transition to a lamellar phase. The
first membrane protein structure from lipidic cubic phase crystallization, bacteriorhodopsin, was
published in 1997 [22]. The method attracted attention with the crystal structures of the GPCRs
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Figure 1.2: Crystal structures of membrane proteins with crystallization chaperones: A) KcsA in
complex with Fab fragments. For clarity, only two subunits of the tetramer are shown (PDB ID
1K4C, [24]). B) Full-length KcsA with two Fab fragments (PDB ID 3EFF, [25]). C) ClC (PDB
ID 1OTS, [26]). D) AcrB trimer in complex with two DARPin binders (PDB ID 2J8S, [27])
β2-adrenergic receptor and A2A adenosine receptor. Modifications of the lipidic cubic phase
method are lipidic sponge phase and lipidic bicelle crystallization. A review of the method
providing a list of deposited structures was published by Johanson et al. [23].
Crystallization chaperones
Successful crystallization occurs from a supersaturated solution following a nucleation event.
Nucleation is more likely to occur in a monodisperse sample. In addition to high purity and
the absence of aggregates, conformational homogeneity is desirable. Movement of the pro-
tein or high flexibility of loops or termini can prevent crystallization by increasing the entropic
cost of lattice formation [28]. Receptors and transporters, however, need to accomodate differ-
ent conformations during signal transduction or substrate translocation. Accordingly, multiple
structures capturing different states of the protein in action allow the understanding of the mode
of operation. Ligands or inhibitors are often used to this end. If these are not available or do
not lead to successful structure determination for other reasons, artificial binding proteins can be
evolved to stabilize a certain conformation. In addition, proteinaceous binding partners increase
the hydrophilic surface that is available for crystal contacts. This is important since a large part
of the membrane protein surface is shielded by the detergent micelle.
Various scaffolds are available for the evolutionary design of protein binders. In addition to
8 CHAPTER 1. INTRODUCTION
antibody-derived molecules such as Fab or scFv fragments, or the smaller nanobodies, lipocalin-
derived anticalins [29], fibronectin type III domain (FN3) and designed ankyrin repeat proteins
(DARPins) have been successfully used as binding proteins and crystallization chaperones [30].
DARPins have several advantages over antibody fragments such as exceedingly high stability
and high expression yields in a bacterial host [31].
Figure 1.2 shows several crystal structures of membrane proteins in complex with a crys-
tallization chaperone. A high-resolution structure of the transmembrane part of the potassium
channel KcsA [24] was obtained with the help of Fab fragments. The Fabs are bound to every
chain of the symmetrical tetramer and provide all crystal contacts. The first structure of the
full-length channel was solved with the help of Fab fragments targeting the cytoplasmic part of
KcsA and stabilizing the closed conformation of the highly dynamic molecule [25]. The crystal
structure of Escherichia coli ClC was determined at a resolution of 2.5 Å in complex with a
Fab fragment, while crystals of the ion channel without binding partner diffracted to 3.5 Å [26].
The multidrug efflux pump AcrB from Escherichia coli is the first membrane protein that was
crystallized in complex with DARPin binders. The structure provided a higher resolution model
of the transporter in an asymmetric conformation [27]. Chapter 4 presents a detailed evaluation
of the use of DARPins as crystallization chaperones for AcrB.
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Chapter 2
Expression of rat Ntcp in
baculovirus-infected insect cells
2.1 Introduction
2.1.1 Bile formation and function
Human bile is formed in two steps: Bile fluid is produced by hepatocytes and modified by
cholangiocytes during passage through the long bile ducts. Bile, composed of water, bile acids,
phospholipids, cholesterol, proteins and salt, is stored in the gall bladder and released into the
duodenum upon stimulus following food-intake. The classical role of bile salts is the emulsifi-
cation of lipids and lipid-soluble vitamins in the intestine. More recently, additional functions
have been discovered. It has been found that bile acids are signalling molecules actively in-
volved in cholesterol metabolism, lipid and carbohydrate homeostasis. Therefore, the bile acid
concentration in the intestine and the hepatocyte needs to be tightly controlled.
The synthesis of bile acids is regulated by negative feedback: Binding of bile acids to farne-
soid nuclear receptor (FXR) down-regulates the transcription of cholesterol 7α-hydroxylase, the
rate-limiting enzyme for bile acid synthesis from cholesterol [1]. Moreover, bile acid activated
FXR is a key regulator of genes crucial for hepatic fatty acid and triglyceride synthesis [2]. In
addition, bile salts have been found to act as endocrine activators on the G-protein coupled re-
ceptor TGR5 [2,3]. In response to bile acid binding, this receptor has a tissue-specific effect on
energy and glucose homeostasis. In this context, TGR5 is studied as a potential drug target for
the treatment of metabolic disorders such as type 2 diabetes and obesity [4].
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Figure 2.1: Structural features of bile acids: A) Chemical formula of common bile acids and
their conjugates, adapted from [6] B) Stick representation of taurocholate based on PDB ID
2AZZ [7]. C) Taurocholate molecule in sphere representation illustrating the amphiphatic nature
of the molecule.
Primary bile acids are synthesized in hepatocytes from cholesterol [5]. In the classical path-
way, 17 enzymatic reactions are required to convert the starting product to a conjugated bile
acid. The rate-limiting step is the hydroxylation of C7 of the steroid nucleus by cholesterol
7α-hydroxylase. Bile acids consist of a sterole with two methyl groups at C10 and C13. An
isopentenyl or isooctanyl side chain is attached at C17 carrying the carboxyl group (C24 or C27
bile acids depending on the position of the functional group). While all bile acids contain the
C3 hydroxy group of cholesterol and the C7 hydroxy or oxo group, they differ in the position
and orientation of additional hydroxyl groups. The most common bile acids in human bile are
chenodeoxycholic acid, cholic acid and deoxycholic acid (Figure 2.1 A). The first two are pri-
mary bile acids, while the latter is formed when cholic acid is dehydroxylated by bacteria in the
intestine, and is therefore referred to as a secondary bile acid.
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While cholesterol is a planar, poorly water-soluble compound that physiologically resides
in eukaryotic membranes, bile acids are bent molecules with an apolar and a hydrophilic side
(Figure 2.1B and C, [8]) and greatly improved solubility. This detergent-like property enables
them to form micelles and emulsify hydrophobic substances such as lipids or lipid-soluble vi-
tamins in the intestine, but also gives rise to the cytotoxicity of bile salts at high concentration.
In their physiological form, bile acids are conjugated to the amino acids taurine or glycine. The
ionic charge of the resulting bile salts enhances water solubility and prevents the molecules from
passing membranes. Protein-mediated transport is therefore required for bile salts to cross the
lipid bilayer.
2.1.2 Enterohepatic circulation of bile salts
The major part of bile acids is reabsorbed in the small intestine and returns to the liver after ac-
tive transport through enterocytes and hepatocytes. This recycling process termed enterohepatic
bile salt circulation is tightly connected with lipid homeostasis and cholesterol metabolism.
Various reviews describe the enterohepatic circulation of bile salts (e. g. [8,9]). Figure 2.2
gives an overview over the proteins involved in humans as well as their location and driving
force. After their synthesis in hepatocytes, glycine- and taurine-conjugated bile acids reach the
canaliculus via ATP-hydrolysis-driven transport by the bile salt extrusion pump (BSEP) residing
in the canalicular membrane of hepatocytes. Transport occurs against a concentration gradient
since bile salts are strongly enriched in the canaliculus. Bile is modified in the bile duct by
electrolyte transport proteins such as the cystic fibrosis transmembrane conductance regulator
(CFTR) and the chloride/bicarbonate exchanger (AE2) which are expressed in the apical mem-
brane of cholangiocytes (not shown). Bile is stored in the gall bladder and its release into the
duodenum is triggered by intestinal hormones. In the small intestine, bile is passed along via
peristalsis. In addition to emulsifying water-insoluble food components, bile salts affect diges-
tion, for example through the regulation of pancreatic secretions [10] or activation of carboxyl
ester lipase [11].
In the ileum, about 95 % of bile acids are reabsorbed into enterocytes by the apical sodium-
dependent bile salt transporter (ASBT). The heterodimeric transporter OSTα/OSTβ [12] translo-
cates the molecules across the basolateral membrane where they are transported back to the liver
via portal blood. The main uptake system from sinusoidal blood into hepatocytes is the sodium
taurocholate cotransporting polypeptide (NTCP). The sodium gradient driving the transport is
maintained by the Na+K+ ATPase. Sodium-independent organic anion transporting proteins
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(OATPs) are also capable of transporting bile salts across the basolateral membrane of hepato-
cytes, but mainly in their unconjugated forms.
Disturbances of the enterohepatic bile salt circulation are associated with disease. Blockage
of bile flux can be hereditary when it is caused by mutation of one of the hepatocyte ABC trans-
porters as it is the case in progressive familial intrahepatic cholestasis (PFIC, for a recent review
see [13]). Drug-induced cholestasis, sepsis-associated cholestasis and intrahepatic cholestasis
of pregnancy are caused by inhibition or decreased expression level of these transporters [9].
Accumulation of bile acids in hepatocytes ultimately causes liver injury. Malabsorption of bile
acids from the intestine leads to cologenic diarrhea. High levels of bile acids are also associated
with intestinal inflammation and colon cancer.
Although NTCP/Ntpc and ASBT/Asbt have not been related to disease, their impact on
bile salt homeostasis makes them pharmacologically interesting. In industrialized countries,
the most common cause of death is cardiovascular disease. High cholesterol level is a risk
factor for artheriosclerosis, in particular at higher LDL concentration, increasing the likelihood
of heart attack or stroke. Since bile acids are a catabolic end product, their synthesis is the
main means of removing cholesterol from the body. This fact has been exploited by blocking
the enterohepatic circulation. Drugs targeting ASBT/Asbt aim to prevent artherosclerosis by
lowering cholesterol levels in hepatocytes. Several classes of specific inhibitors, some of which
are bile salt analogons, met these goals in animal studies (reviewed by [14]). In addition, there
is interest in using SLC10 transporters as a shuttle system for prodrugs ( [6,15]). Conjugation to
bile acids while maintaining the properties of a good ASBT/Asbt substrate can greatly improve
the oral bioavailibility of drugs. This approach has been followed by Kramer and Wess. One
example is the design of a liver-specific inhibitor of the key enzyme of cholesterol synthesis,
HMG-CoA reductase, by combining a statin with a bile acid [16]. The goal is to minimize
side-effects in other tissues during cholesterol-lowering therapy.
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Figure 2.2: Enterohepatic circulation of bile salts: After their synthesis in the liver, bile salts
are secreted into the bile canaliculus by ATP-driven transporters such as BSEP, MRP2, MDR3
or ABCG5/G8. Reabsorption in the ileum is driven by ASBT. OATPs and ABC transporters
translocate bile acids into the portal blood. From there, uptake into hepatocytes across the baso-
lateral membrane is mediated mainly by NTCP, but also various OATPs.
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2.1.3 Sodium-dependent bile acid transporters of the Slc10 family
Sodium-dependent uptake of bile acids which accounts for 80 % of the transport has been studied
in basolateral rat liver plasma membrane vesicles [17]. The protein responsible for this activity
was later identified by expression cloning [18] in Xenopus laevis oocytes. The 51 kDa glycopro-
tein termed sodium-taurocholate cotransporting polypeptide (NTCP/Ntcp1) is the major player
of taurocholate uptake across the basolateral membrane of hepatocytes. When the translation of
the transporter is blocked by Ntcp-specific antisense oligonucleotides, sodium-dependent tauro-
cholate uptake is decreased by 95 % in rat liver total mRNA injected oocytes ( [19]).
The apical sodium bile salt transporter (ASBT/Asbt1), also referred to as ileal bile acid trans-
porter (IBAT), is highly homologous to NTCP/Ntcp. Expressed in the brush border membrane
of enterocytes, it mediates the reabsorption of bile acids in the ileum. The protein is also found
in biliary epithelial cells and renal proximal tubuli.
NTCP/Ntcp and ASBT/Asbt are grouped into the SLC10 superfamily of sodium bile acid
transporters that currently holds 29 members, among them seven human proteins. Their trans-
port activity was studied in various eukaryotic cell lines as well as Xenopus laevis oocytes.
While both NTCP/Ntcp and ASBT/Asbt transport conjugated bile acids with high affinity, the
substrate range of NTCP/Ntcp also includes the steroid sulfates estrone-3-sulfate and DHEAS,
bromosulfophthalein [20] and the drug-conjugate chloroambucil-taurocholate [21]. Some fam-
ily members, like the sodium organic anion transporter (SOAT), do not transport bile acids, but
other organic anions [22]. The secondary active transporters use the sodium gradient main-
tained by the Na+ K+ ATPase to translocate their substrates in an electrogenic manner, with
two sodium ions translocated along with one taurocholate ion [23].
Structural information on SLC10 superfamily members is based on computational sequence
analysis. There has been controversy about the number of transmembrane helices. For human
ASBT, a seven-transmembrane model was experimentally validated [24]. The N-terminus is
located in the extracellular space while the C-terminus is in the cytoplasm. Figure 2.3 shows a
7-helix topology model of rat Ntcp based on a sequence alignment with human ASBT.
Functional analysis of rat Ntcp mutants led to the identification of residues important for
transport activity [25]. Two negatively charged residues, D115 and E257, have been found to
be crucial for transport. Both are located in loops. This led to the P-loop hypothesis for the
transport mechanism. The negatively charged residues are thought to serve as binding sites for
1All capital letters when referring to the human protein, only the first letter in upper case for its homologs from
other organisms.
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Figure 2.3: Topology model of rat Ntcp (Slc10a1) with seven transmembrane spanning helices.
The signature motif for SLC10 family members is colored yellow. A potential glycosylation site
is marked in the N-terminal part. Residues D115 and E257 are highlighted in green. Based on
a ClustalW alignment of all SLC10 family members, residues are shaded in gray according to
their degree of conservation.
the sodium ions. According to the proposed mechanism, the loops containing these residues
would insert into the membrane in a P-loop fashion during cotransport of the substrates, similar
to the re-entrant loops found in later crystal structures of sodium cotransporters.
A recent publication reported the functional importance of transmembrane helix III in human
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ASBT [26]. In particular a proline, which is conserved in all members of the Slc10 family, was
identified by the mutational study. Prolines are considered helix breakers because they cannot
act as a hydrogen bond donor. A proline in a transmembrane segment would therefore cause a
kink or partial unwinding of the helical structure.
2.1.4 Structural features of sodium transporters
Recently, several crystal structures of sodium-dependent bacterial transporters have been de-
termined (Figure 2.4). Although unrelated to the SLC10 superfamily, the structures provide
insight into the mechanism of sodium-coupled transport (reviewed by [27]). The glutamate
transporter homologue from Pyrococcus horikoshii was the first sodium cotransporter with an
atomic-resolution structural model (PDB ID 2NWX, [28]). Each chain of the homotrimer con-
tains two re-entrant hairpin loops forming a pseudo-symmetrical structure with an interrupted
transmembrane helix. The substrate as well as two sodium binding sites are located in the partly
unwound helix. The two hairpin loops prevent the dissociation of glutamate from the transporter.
A conformational change would be required to release the substrate.
LeuT (PDB ID 2A65, [29]), vSGLT [30] and Mhp1 [31] are other sodium-coupled trans-
porters with known crystal structures that share a common fold despite a differing number of
transmembrane helices. All structures show a pseudosymmetrical motif formed by two bundles
of five transmembrane helices (5+5 motif) with a central substrate and ion binding site at the
interface of two interrupted transmembrane helices.
The crystal structure of the sodium/H+ antiporter NhaA (PDB ID 1ZCD, [32]) from Es-
cherichia coli shows a 12 transmembrane helix architecture. As observed in the structures of
sodium cotransporters, interrupted helices form the binding site for the ions. Disruption of
transmembrane helices in ion transporters is therefore a reoccuring observation that might also
be present in proteins from the SLC10 family. Discontinuation of the secondary structure leads
to a hydrophilic environment caused by exposed main chain atoms, allowing the binding of ions
in the otherwise hydrophobic core of the protein.
With the increasing number of membrane protein structures, we understand that the archi-
tecture of membrane protein is often much more complex than a simple arrangement of helices
perpendicular to the membrane plane. Long helices can cross the membrane at an angle. Re-
entrant hairpins, kinks and adjacent helices are possible. In particular the translocation of ions
requires a hydrophilic binding site shielded from the lipid environment. Experimental structural
data is therefore essential to explain observations from mutational analysis.
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Figure 2.4: Membrane topologies and crystal structures of the sodium-cotransporters GltPh and
LeuT as well as the sodium antiporter NhaA. In both the topology and the structure representa-
tion, interrupted helices are shown in red, and hairpin loops are colored green. Helices flanking
these functional elements are in purple. The rest of the structures is colored in blue. For clarity,
one chain of the crystal structures is in ribbon representation, while red, green or purple ele-
ments are shown as cartoon. The models for GltPh and LeuT contain bound substrate (yellow)
and sodium ions (orange) depicted as spheres.
2.1.5 Aim of the project
Members of the SLC10 superfamily have so far been characterized using transport assays in
membrane vesicles. Although membrane preparations can be fractionated, such as during the
preparation of basolateral membranes from liver homogenates, the vesicles will contain a mul-
titude of other proteins. In order to study the biochemical and biophysical properties of the
isolated transporter, it is desirable to work with pure protein in a solubilized form. Overexpres-
sion of functional protein is the first step in providing material for the purification of a protein
and ultimately arriving at quantities of homogeneous protein for structural studies.
The aim of this project is the functional overexpression of Ntcp fused to a purification tag
using baculovirus-infected insect cells. We evaluated the quantity and quality of the protein after
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Figure 2.5: Generation of a recombinant bacmid by Tn7 transposition: (A) Schematic of the
integration of a gentamycin resistance gene (GmR) along with the Ntcp construct under control
of a polyhedrin promoter (pPolh). When integration takes place, a lacZ gene is interrupted. The
integration site is flanked by M13 primer binding sites. (B) Analytical PCR using M13 primers.
The negative control results in a 300 bp product. Successful transposition with pFastBac-Ntcp-
His or pFastBac-Ntcp-Strep yields a PCR product of 3500 bp.
solubilization and purification. Based on the presented experiments, we suggest a strategy for
the optimization of the expression and purification of Ntcp for structural studies.
2.2 Results
2.2.1 Generation of recombinant baculovirus stocks
Recombinant bacmids for the expression of full length Ntcp from Rattus norvegicus (Slc10a1)
were generated by Tn7 transposition in Escherichia coli DH10Bac using pFastBac containing
the gene modified with a C-terminal His- or Strep-tag, respectively. Successful transposition
leads to the disruption of a lacZ gene (Figure 2.5 A), allowing for blue-white screening of
transformants. Since the Tn7 site on the bacmid is flanked by M13 primer binding sites, the
integration of the gene was confirmed by PCR. Bacmids isolated from white colonies were used
as template, and the bacmid from a blue colony served as a negative control. The resulting prod-
uct is 3500 bp long, confirming the integration of the 1200 bp Ntcp gene along with the flanking
sequence, while the negative control shows a 300 bp product (Figure 2.5 B).
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Figure 2.6: (A) Uptake of [3H]-taurocholate by Sf9 cells three days post-infection. (B) Western
blot of Sf9 membranes from cells three days post-infection with WT, Ntcp-His or Ntcp-Strep
baculovirus using α-Ntcp antibody.
Table 2.1: Titer of P1 baculovirus stocks
Construct Virus titer [infectious particles/ml]
Ntcp-His 1.1 · 108
Ntcp-Strep 0.8 · 108
Baculovirus stocks were prepared by transfection of insect cells with recombinant bacmid.
The titer of the virus stocks after one round of amplification (P1) was around 1 · 108 infectious
particles per ml as determined by end-point dilution (Table 2.1). This virus titer is in a good
range for infection of insect cells for protein production.
2.2.2 Taurocholate transport by baculovirus-infected Sf9 cells
Sf9 cells do not contain a sodium-dependent transport system for taurocholate. The presence of
functional Ntcp can therefore be demonstrated by uptake of this substrate in a sodium-dependent
manner by Ntcp-expressing insect cells 2.6. Three days after infection with Ntcp-containing or
wild-type baculovirus, the transport activity of cells in buffer containing sodium was compared
to the behaviour in a sodium-free control buffer. The latter contained choline chloride instead of
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sodium chloride to generate the same ionic strength. Cells infected with wild-type baculovirus
did not show a significant uptake of [3H]-taurocholate, whereas in Ntcp-virus-infected cells, the
transport activity in sodium-buffer was 30 to 40 times higher than in choline buffer (Figure 2.6
A), confirming the presence of Ntcp in a functional state.
In order to verify the exression of Ntcp, we prepared membrane vesicles from Sf9 cells
infected with Ntcp-baculovirus three days post-infection. A specific antibody for Ntcp detected
the protein when analyzed by western blot, while no signal was observed for Sf9 vesicles from
WT-baculovirus infected cells (Figure 2.6 B). The band appears at an apparent molecular weight
of 35 kDa, with a larger molecular weight species around 38 kDa. The theoretical molecular
mass of rat Ntcp is 39.3 kDa. Due to their hydrophobicity, membrane proteins are known to
migrate at a smaller molecular weight than soluble proteins. The presence of two bands suggests
that Ntcp partly underwent posttranslational modification such as glycosylation. When detecting
Ntcp in basolateral membranes prepared from rat liver homogenates, the apparent molecular
weight of the transporter is 51-55 kDa [33]. Hence, the natural protein is subject to much
more extensive post-translational modification as compared to Ntcp expressed in insect cells.
However, the difference in glycosylation does not seem to prevent taurocholate transport.
2.2.3 Small-scale purification of Ntcp-His
A culture of Sf9 cells was infected with Ntcp-His baculovirus for small-scale purification. We
used SMS buffer that has previously been established for transport studies in Sf9 vesicles. The
protein was solubilized from Sf9 vesicles using foscholine-16. This detergent has been shown
to efficiently solubilize the transporter [34]. After affinity chromatography, we analyzed sam-
ples at every step of the purification process. Although the protein is not visible on SDS PAGE
due to the low amount and poor purity, western blot analysis shows that the protein is enriched
in the eluate (Figure 2.7 A). We used analytical size exclusion chromatography to evaluate the
monodispersity of the protein (Figure 2.7 B). The fractions were TCA-precipitated and analyzed
by western blot using a specific α-Ntcp antibody. Ntcp was detected as a single band eluting
between 10 and 15 ml. Only a small part of the protein is found in the void volume of the col-
umn which is around 8 ml. We conclude that Ntcp is not aggregated, but exists in a variety of
oligomeric states. This inhomogeneity does not seem to arise from post-translational modifica-
tions, since only a single band is detected on the western blot. The apparent molecular weight
is now between 40 and 50 kDa. This corresponds to the mass expected for Ntcp and may be
an effect of TCA precipitation on the migration behaviour of the protein. We estimate that the
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Figure 2.7: A) SDS PAGE and western blot of Ntcp-His at various stages of affinity chromatog-
raphy: Lane 1) rat liver basolateral membranes, 100 µg total protein; lane 2) WT-baculovirus
infected Sf9 vesicles, 100 µg total protein; lane 3) supernatant after solubilization of Sf9 cells;
lane 4) flow-through of affinity purification using Ni-NTA agarose; lane 5) wash with 50 mM
imidazole; lane 6 and 7: fractions of elution with 200 mM imidazole. B) Size exclusion profile
of Ntcp-His on a Superdex 200 10/300 GL in SMS, 0.04 % Fos-16 and western blot of fractions.
purification from 100 ml of Sf9 suspension culture yields approximately 100 µg of Ntcp-His.
When repeating the same experiment with Ntcp-Strep, we find that the transporter only partly
binds to streptavidin matrix during affinity purification and we do not detect protein in the eluate
(not shown). Aggregation of this construct might lead to inaccessibility of the purification tag.
Since the 9-amino acid Strep tag contains a tryptophan, its hydrophobicity might cause it to
interact with the hydrophobic protein or to partition into the detergent micelle.
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2.3 Discussion
We have expressed rat Ntcp with a C-terminal purification tag using baculovirus-infected Sf9
cells. The protein is functional both when fused to a His-tag or a Strep-tag as shown by a
transport assay in whole cells. The identity of the protein was confirmed by western blot analysis
using a specific antibody. Functional expression is the first step towards the purification of a
protein from a recombinant source.
We were able to solubilize the transporter from insect cell membranes and the protein was
enriched during affinity purification via its His-tag. The gel-filtration profile showed that the
protein eluted in a broad peak, with only a small part in the void-volume. This may be due
to multiple oligomeric states of the protein. The native oligomeric state of Slc10 proteins is
not known. The yield and purity are poor. However, the amounts of purified protein would
be sufficient for functional reconstitution in proteoliposomes. A reconstituted system allows
the researcher to control buffer conditions inside and outside of the liposome as well as the
membrane composition.
Based on the presented results, we suggest a strategy to improve yield and quality of the pro-
duced protein. Since the purification tag does not interfere with functional expression of Ntcp,
we propose constructs more suitable for the screening process and for crystallization. A GFP-
tagged Ntcp would not only give qualitative information as only correctly folded GFP-fusions
show fluorescence, but would also allow for efficient screening of various detergents and buffer
conditions monitoring the stability of the protein by fluorescent size exclusion chromatography
before purification [35]. The optimization of the detergent is a critical step since not only quan-
tity of extracted protein, but its integrity needs to be considered. The broad elution profile when
analyzing Ntcp-His by gel filtration suggests that foscholine-16 disrupts the native state of the
transporter and a more mild detergent needs to be used.
Ntcp contains a glycosylation site at position 10 in its N-terminal tail. The corresponding
site has been experimentally confirmed for human ASBT, while other potential glycosylation
sites were found unmodified [24]. Although various crystal structures of glycosylated proteins
have been solved [36], removing glycosylation sites might be necessary to obtain a homogeneous
sample for crystallization. On the other hand, glycosylation is often used as quality control in the
endoplasmatic reticulum of eukaryotic cells before the protein is incorporated into the plasma
membrane. Whether or not unglycosylated Ntcp would be targeted to the plasma membrane can
only be found out experimentally. Also here, a GFP-tagged construct would allow to answer
this question at an early stage. In addition, Ntcp sequestered intracellularly would not prove
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functional, as could be easily tested in transport experiments.
The current expression level does not allow for structural studies. Bacterial homologs of
sodium taurocholate cotransporters are an alternative. A screen to identify a well-behaving
homologous protein that yields high amounts when overexpressed in Escherichia coli might
lead to faster structure determination. Information on the structure of SLC10 homologs would
provide first insight into the architecture and transport mode of SLC10 proteins and allow for
the calculation of a more accurate structural model of the eukaryotic transporters.
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2.4 Experimental procedures
2.4.1 Maintenance of insect cell cultures
For all experiments, the cell line Sf9 derived from the fall army worm Spodoptera frugiperda
was used. If not stated otherwise, cells were cultivated in Sf-900 II SFM (serum-free medium,
Gibco) supplemented with 100 U/ml penicillin/streptomycin (supplier). All manipulations of
insect cell cultures were carried out under sterile conditions in a laminar flow hood.
Thawing of insect cells
To initiate a culture from a frozen stock, the cell suspension was thawed rapidly in a waterbath
heated to 37 degrees. After decontamination of the outside of the vial, the cells were immediately
transferred into 10 ml of Sf-900 II SFM to dilute the cryoprotectant. After centrifugation at
500 g for 5 min, the cell pellet was carefully resuspended in 10 ml of fresh medium containing
100 U/ml penicillin/streptomycin and transferred into a 10 cm cell culture dish. The cells were
incubated in a humidified incubator at 27 degrees.
Passaging
Adherent culture Sf9 cells were grown in monolayers in cell culture dishes (Corning, product
number). Per 10 cm dish, 5 ·106 cells were seeded in 10 ml medium. The cells were split at 80 to
100 % confluency to maintain log-phase growth. For this purpose, adherent cells were detached
by pipetting and diluted in medium prefilled in fresh cell culture dishes. Typically, 1:3 dilution
three times per week were sufficient.
Suspension culture Suspension cultures of Sf9 cells were grown in glass flasks at 27 degrees
and 90 rpm. The cultures were kept at exponential growth by diluting them to 0.8− 1 · 106 cells
per ml every two to three days. Cell densities higher than 3 ·106 cells per ml were avoided. Used
flasks were washed with 30 % acetic acid and 70 % ethanol prior to cleaning in the dishwasher
with destilled water. The flasks were autoclaved before use.
Freezing of Sf9 cells
To prepare frozen stocks of Sf9 cells, culture with a viability greater than 95 % were used.
Cells were harvested at mid log phase growth by centrifugation at 500 g for 5 min and resus-
pended in cold cryomedium (Sf-900 II SFM supplemented with 10 % DMSO and 100 U/ml
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penicillin/streptomycin) to a density of 2 ·107 cells/ml. 1 ml aliquots of the cell suspension were
prepared in cryo vials and placed in an isopropanol bath for slow cooling to -80 degrees. Frozen
Sf9 stocks were ideally stored in liquid nitrogen, alternatively at -80 degrees.
2.4.2 Generation of recombinant baculovirus
Cloning of Ntcp in pFastBac
The full-length rat ntcp gene was amplified by PCR using the primers BamHI-Ntcp and Ntcp-
HindIII from the template pSPORT-Ntcp [18]. The resulting product carried the sequence of
the Ntcp gene with a BamHI restriction site upstream and a XbaI site, two in-frame stop codons
followed by a HindIII restriction site downstream of the open reading frame. The purified PCR
product and pFastBac were digested with 5 U BamHI and 5 U HindIII in seperate reactions.
After gel-purification of the fragments, the Ntcp gene was ligated into pFastBac.
In order to fuse the Ntcp gene with a C-terminal purification tag, a 6xHis or a Strep-tag with
sticky ends corresponding to the restriction enzymes XbaI and HindIII was made by hybridiza-
tion of the complementary primers Xba-His-for and Xba-His-rev or Strep-for and Strep-rev,
respectively. To this end, 1 pmol each of the complementary primers was mixed in 20 mM
Tris/HCl pH 7.5, 50 mM NaCl and 2 mM MgCl2 in a total volume of 10 µl. The hybridization
reaction was incubated at 80 degrees for 5 min and then slowly cooled to room temperature. The
fragments were ligated in pFastBac-Ntcp digested with XbaI and HindIII. After verifying the
sequence using Microsynth standard primers FastBacf and FastBacr, the plasmids could be used
for the generation of recombinant bacmid.
Generation of recombinant bacmid
Escherichia coli strain DH10Bac contains a baculovirus shuttle vector (bacmid) that confers
kanamycin and gentamycin resistance. A segment of the bacmid encodes the LacZα peptide in
which a Tn7 site for bacterial transposition has been inserted. When a gene is integrated in the
baculovirus genome at this site, the open reading frame of the LacZα peptide will be disrupted,
allowing for blue-white selection of transformants in presence of X-gal. In addition, the inte-
gration site is flanked by M13 primer binding sites. The bacteria also harbour a helper plasmid
conferring resistance to tetracycline. This plasmid encodes for the transposase catalyzing the
Tn7 recombination reaction.
DH10Bac cells were made electrocompetent according to the following procedure: A 100 ml
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culture of DH10Bac cells in LB medium was grown at 37 degrees and 230 rpm in LB containing
kanamycin and tetracyclin. At OD600 = 0.5, the culture was cooled for 15 min on ice and
the cells were pelleted by centrifugation at 4000 rpm for 15 min at 4 degrees. The pellet was
resuspended four times in a decreasing volume of ice cold, sterile 10 % glycerol. In the first
cycle, 100 ml were used, followed by 50 ml, 2 ml and 200 µl. Competent cells were used
immediately or aliquots were snap-frozen in liquid nitrogen and stored at -80 degrees.
20 µl of competent DH10Bac cells were electroporated with 5 ng of the isolated pFastBac
plasmid. The cells were immediately resuspended in 4ml 2xYT medium and allowed to recover
for 6 h at 37 degrees and 230 rpm. Subsequently, 200 µl of the cell suspension was streaked out
on LB plates containing 100 µg/ml ampicillin, 50 µg/ml kanamycin, 10 µg/ml tetracyclin, 7
µg/ml gentamycin, 100 µg/ml X-gal and 1 mM IPTG.
Isolation of the bacmid
Single white colonies were used to inoculate 5 ml LB containing 50 µg/ml kanamycin, 10
µg/ml tetracyclin and 7 µg/ml gentamycin. Blue colonies were used to isolate bacmid for
a negative control. The cultures were grown over night at 37 degrees and 230 rpm. In order
to isolate the bacmid, the cells were pelleted by centrifugation and resuspended in 300 µl of
solution I (15 mM Tris/HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNAse A, filtered 0.2 µm).
Alkaline lysis of the cells took place during 5 min after mixing with 300 µl of solution II (0.2 N
NaOH, 1 % SDS, filtered 0.2 µm). Then the solution was neutralized by adding of 300 µl
of solution III (3 M potassium acetate, pH 5.5, autoclaved). The sample was placed on ice
for 10 min. The thick, white precipitate was removed by centrifugation at maximum speed
for 10 min. In order to precipitate the bacmid DNA, the supernatant was transferred into a
tube containing 800 µl isopropanol. After placing the tube on ice for 10 min, the sample was
centrifuged at maximum speed for 15 min. The pellet was washed twice with 70 % ethanol and
afterwards allowed to air dry at room temperature for 10 min. The DNA was resuspended in
100 µl 10 mM Tris/HCl pH 8.0 and the concentration determined by measuring the absorption
at 260 nm. Purified bacmid DNA was stored at 4 degrees.
Analysis of recombinant bacmid DNA
To verify the integration of the Ntcp gene in the bacmid by Tn7 transposition, analytical PCR
was performed making use of the M13 primer binding sites flanking the integration site. 1 µg
of bacmid DNA, 1 µl of 10x Thermo Pol buffer, 0.2 µl of 10 mM dNTPs, 0.2 µl of 100 mM
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MgSO4, 2.5 pmol of M13 for, 2.5 pmol of M13 rev and 0.1 µl of Taq polymerase were mixed
in a total volume of 10 µl. The reaction was placed in a thermocycler and heated to 93 degrees
for 3 min. After 25 cycles of 94 degrees for 45 s, 55 degrees for 45 s and 72 degrees for 5
min, a final extension at 72 degrees for 7 min was performed before cooling to 4 degrees. The
products were analysed on a 1 % agarose gel. Blue colonies and negative clones resulted in a
PCR product of 300 bp, whereas bacmids successfully transposed with pFastBac produce a band
at 2300 bp larger than the size of the insert. In the case of Ntcp, a 3500 bp product confirms the
presence of the Ntcp gene on the bacmid.
Transfection
For the transfection of Sf9 cells with recombinant bacmid, cellfectin (Invitrogen) was used as a
transfection agent according to the manufacturer’s instructions. Briefly, 9·105 cells per well were
seeded in sterile 6-well plates with 2ml per well of Baculo Gold medium containing 100 U/ml
penicillin/streptomycin. The cells were allowed to attach at 27 degrees for one hour. In the
meantime, for each transfection 1 µg of recombinant bacmid DNA diluted in 100 µl Baculo
Gold medium was combined with 6 µl of cellfectin diluted in 100 µl medium and incubated for
45 min at room temperature.
Transfections were performed in duplicates with untransfected Sf9 cells as a control. The
cells that should now adhere to the plate were washed once with 2 ml medium. After removing
the wash medium, the DNA:lipid complexes were diluted with medium to a total volume of 1 ml
and added to the wells containing cells. The plates were incubated at 27 degrees for 5 hours.
Then the DNA:lipid complexes were removed by aspiration and 2 ml of Sf-900 serum-free
medium containing antibiotics were added. The cells were incubated at 27 degrees until signs
of viral infection such as swelling and detachment from the plastic surface became visible. This
typically took 3 to 4 days. At this point, the P0 virus stock was recovered. The supernatant was
clarified by centrifugation at 500 g and filtered through a 0.2 µm syringe filter. The supernatant
constituting the P0 virus stock was stored at 4 degrees protected from light.
Amplification of virus stocks
P0 baculovirus stocks were amplified by infecting a 50 ml suspension culture of Sf9 cells. For
each amplification, a culture containing 0.6 · 106 cells per ml was infected with 250 µl of the
P0 virus stock. One flask was left uninfected for comparison. The cultures were incubated at 27
degrees and 90 rpm and the number of cells and their viability was monitored. To this end, an
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aliquot of the cell suspension was mixed with equal volume of Trypan blue. This dye selectively
stains dead cells. The cells were counted using a Thomas counting chamber and the fraction of
viable cells was determined by dividing the number of cells that were able to exclude Trypan
blue by the total number of cells. Virus was harvested when the cells had stopped growing for
24 hours and the viability started to decrease. To recover the P1 virus stock, the culture was
centrifuged for 5 min at 500 g and the supernatant was filtered using a 0.2 µm syringe filter. The
titer was determined as described in 2.4.2 and the virus stock was stored at 4 or -80 degrees.
Titer determination by end point dilution
In order to determine the titer of a baculovirus stock, a Sf9 cell suspension with 2.5 ·104 cells/ml
was prepared and 200 µl were added to each well of a 96-well plate suitable for tissue culture.
The cells were allowed to adhere for 1 hour at 27 degrees. 100 µl of a 1 in 1000 dilution of the
virus stock in medium was added to the central 6 wells (B1-G1) of the first column of the plate.
Wells A1 and H1 served as controls after addition of 100 µl medium. A 12 step 3 times serial
dilution of the medium containing the virus stock was prepared by transferring 100 µl from the
first to the second column and repeating this step until column 12 was reached. The plates were
incubated at 27 degrees in a humidified incubator for 12 days to allow virus particles to infect
the cells. After this time, wells that contained any baculovirus particles would not hold viable
cells. Thiazolyl Blue Tetrazolium Blue (MTT, Sigma) was used to detect cell viability. The
reagent is a yellow substance that is converted to a water-insoluble, dark blue MTT-formazan by
mitochondrial dehydrogenases of living cells. 25 µl of a 5 mg/ml MTT solution were added to
each well. The plates were wrapped in tinfoil to prevent degradation of the light-sensitive dye
and incubated for 3 h at 27 degrees. Subsequently, the supernatant was aspirated and the blue
precipitate dissolved in 95 % isopropanol, 50 mM HCl. After 15 min at room temperature, the
absorbtion at 550 nm was read in a microplate reader. The first virus dilution where 2 of the 6
wells do not show viral infection was multiplied by 5 to calculate the virus titer. A titer ranging
from 1− 9 · 108 infectious particles per ml is desirable.
2.4.3 Assay to measure uptake into Sf9 cells
To confirm the functional expression of Ntcp in Sf9 cells, we measured sodium-dependent trans-
port activity of Sf9 cells using radioactive taurocholate. Sf9 cells for this experiment were
grown in monolayers in Grace’s medium supplemented with 10 % FCS and 100 U/ml peni-
cillin/streptomycin. For each sample, three 10 cm Corning dishes with 5 · 106 ml Sf9 cells
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were infected with the Ntcp or wild type baculovirus stock at a multiplicity of infection (MOI)
of 5. Three days post-infection, the cells were harvested under non-sterile conditions using
a cell scraper. Cells infected with the same virus were pooled and counted. For each sam-
ple, six eppendorf tubes were prepared with 1 · 106 cells each. Three of the tubes served to
measure the transport in sodium buffer (122 mM NaCl, 10 mM MES, 3 mM CaCl2 · 2H20,
5 mM MgCl2 · 6H20, 5 mM D-glucose, pH 6.5) and the other three were used as a negative
control in choline buffer (122 mM choline chloride, 10 mM MES, 3 mM CaCl2 · 2H20, 5 mM
MgCl2 · 6H20, 5 mM D-glucose, pH 6.5). The cells were washed twice by centrifugation at
1000 g, aspiration of the medium and resuspending in 1 ml Grace’s medium supplemented with
100 U/ml penicillin/streptomycin to remove residual FCS. To start the uptake process, the cell
pellet was resuspended in 250 µl 10 µM [3H]-taurocholate (2.5 µCi/ml in sodium or choline
buffer. After incubating the tube for 15 min at 25 degrees and 800 rpm, the uptake was stopped
by addition of 1 ml ice cold choline buffer. The tubes were stored on ice until all samples were
processed. To remove remaining extracellular [3H]-taurocholate, the cells were washed twice
with 1 ml cold choline buffer by centrifugation for 1 min at 1500 g and 4 degrees, aspiration
of the supernatant and resuspending the pellet. After an additional centrifugation step, the cells
were lysed in 250 µl of 1 % triton X-100 during 1 h at room temperature. The total protein
concentration of each sample was determined in a BCA assay according the the manufacturer’s
instructions using 25 µl of the lysate. 150 µl of the lysate were mixed with 4 ml Ultima Gold
in a scintillation counter vial. To relate the radioactivity count to taurocholate concentration, the
[3H]-taurocholate solution in sodium or choline buffer, respectively, was used as a standard. To
this end, 50 µl of each solution were added to 100 µl triton X-100 and 4 ml Ultima Gold in a
scintillation vial. The standards were prepared in triplicates. A scintillation counter was used
to measure the radioactivity from tricium for 5 min per vial. The transport activity was calcu-
lated in pmol taurocholate per mg total protein. For each sample, the mean transport activity in
sodium buffer was compared to the signal in absence of sodium.
2.4.4 Small-scale preparation of vesicles
Vesicles from Sf9 cells were prepared as a partial purification step to be used as samples for SDS
PAGE and western blot analysis, for transport experiments (not described) or for solubilization
of the transporter. Cells were harvested by centrifugation at 3000 rpm for 10 min at 4 degrees
and resuspended in 5 ml cold TMEP (50 mM Tris/HCl pH 7.0, 50 mM mannitol, 2 mM EGTA,
Complete) per 5 · 107 cells. The cells were homogenized using a glass-teflon homogenizer and
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a drill for 20 strokes at full speed while keeping the samples on ice. After centrifugation at
3000 rpm for 10 min at 4 degrees, the supernatant was transferred to ultracentrifugation tubes.
Following centrifugation at 100000 g for 1 h at 4 degrees, the membrane pellet was resuspended
in 100 µl SMS buffer (20 mM HEPES/Tris pH 7.5, 250 mM sucrose, 0.2 mM CaCl2) with a 25
G needle until the solution turned turbid. The total protein concentration was determined using
a BCA assay and the sample stored at -80 degrees after snap-freezing in liquid nitrogen.
2.4.5 Protein purification and analysis
Infection
For small-scale protein expression, a 100 ml suspension culture of Sf9 cells with a density of
1 · 106 cells/ml was infected using the respective P1 virus stock at a MOI of 5. The cell growth
was monitored by performing a viable cell count every 24 h. The cells were harvested at an early
state of infection, typically after 72 h. This state is reached when enlarged cells are observed
and the culture stopped growing. It is important to harvest before the infection causes lysis of
the culture.
Harvesting and membrane preparation
The cells were harvested by centrifugation at 5000 rpm in a 50 ml Falcon tube. After resuspend-
ing the pellet in 20 ml cold TMEP (50 mM Tris/HCl pH 7.0, 50 mM mannitol, 2 mM EGTA,
Complete), the cells were lysed using three rounds of French Press at 4 degrees. Cell debris
was removed by centrifugation at 5000 rpm for 10 min at 4 degrees and the supernatant was
subjected to ultracentrifugation at 45000 rpm (100000 g, Beckman Ti70) for 1 h at 4 degrees.
The membrane pellet was resuspended in 500 µl SMS buffer (20 mM HEPES/Tris pH 7.5, 250
mM sucrose, 0.2 mM CaCl2). The membrane suspension was snap-frozen in liquid nitrogen for
storage at -80 degrees or directly used for solubilization.
Solubilization and purification
The membrane suspension was solubilized in SMS supplemented with 1 % foscholine-16 during
overhead rotation over night at 4 degrees in a total volume of 30 ml. Unsolubilized material was
removed by ultracentrifugation and the supernatant was subjected to affinity chromatography.
Ntcp-His was purified by batch-binding to 500 µl Ni-NTA agarose equilibrated with SMS,
10 mM imidazole, 0.04 % Fos-16 for 30 min at 4 degrees. The suspension was poured into
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a gravity-flow column, washed with 10 column volumes of SMS, 50 mM imidazole, 0.04 %
Fos-16 and eluted in SMS, 200 mM imidazole, 0.04 % Fos-16.
The purification of Ntcp-Strep was carried out similarly by adding 500 µl of StrepTactin
(IBA Biotech, Germany) equilibrated with SMS, 0.04 % Fos-16 to the supernatant after ultra-
centrifugation. After batch-binding for 30 min at 4 degrees, the suspension was poured into
a gravity-flow column and the matrix was washed with 10 column volumes of SMS, 0.04 %
Fos-16. 2.5 mM desthiobiotin in SMS, 0.04 % Fos-16 was used to elute the protein from the
column.
The fractions containing the most protein as judged by measuring absorbance at 280 nm
were analyzed by size exclusion chromatography in SMS, 0.04 % Fos-16 using a Superdex 200
10/30 GL column.
2.4.6 SDS PAGE and Western Blot
Protein samples were analyzed by SDS PAGE using 10-20 % gradient gels. The gels were
either stained with Coomassie Brilliant Blue or the protein was transferred to a nitrocellulose
membrane using the iBlot Dry Blotting System (Invitrogen). The membranes were blocked in
high TBS-T (50 mM Tris/HCl pH 7.0, 500 mM NaCl, 0.2 % Tween20) containing 5 % milk
overnight at 4 degrees. After washing twice for 10 min with high TBS-T, the membranes were
incubated with the primary antibody (K4 rabbit α-Ntcp, 1:5000 in high TBS-T/0.5 % milk) for
2 h at room temperature. Following an additional washing step, the secondary antibody (goat
α-rabbit IgG horse radish peroxidase, Sigma, 1:5000 in high TBS-T/0.5 % milk) was applied
for 1 h at room temperature. Subsequently, the membranes were washed with high TBS-T,
high TBS (50 mM Tris/HCl pH 7.0, 500 mM NaCl) and destilled water twice for 5 min each.
The blots were developed using the ECl kit (GE Healthcare) according to the instructions and
chemiluminescence was read using a LAS-3000 Luminescent Image Analyzer (FujiFilm).
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Chapter 3
Biophysical characterization of the
extracellular loop of Oatp1a4
3.1 Introduction
3.1.1 Membrane transporters involved in drug disposition
The bioavailability of a drug is determined by several factors: Absorption, distribution, metabolism
and excretion affect the ability of a drug to reach its target tissue. After oral administration of a
substance, the efficiency of gastrointestinal uptake limits the absorption of the drug. In addition,
the blood-brain barrier, the blood-placenta barrier or others protect tissues from exogeneous
substances. Finally, compounds are actively removed from the body via hepatic clearance or
elimination in the kidney.
Membrane transporters in the described tissues are responsible for the uptake of a substance
or its extrusion. For the uptake of substances leading either to absorption of the compound or
its elimination from the blood stream, peptide transporters (PEPTs), OATs and Oatps/OATPs
are responsible. ABC transporters are the main extrusion system. Well-studied examples are
P-glycoprotein or multidrug resistance proteins (MRPs).
Due to genetic variation, individuals react differently to the administration of the same drug.
Pharmacogenetic studies addressing this issue are complicated by the diversity of transporters
involved in uptake and elimination of drugs as well as their broad and overlapping substrate
specificity. A detailed mechanistic understanding of the transport, the distribution and the regu-
lation of the proteins executing the transport is therefore crucial for successful drug therapy.
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3.1.2 The SLC21 superfamily of organic anion transporting polypeptides
Organic anion transporting polypeptides (human: OATPs, other species: Oatps) are multispe-
cific transporters [1] that affect the pharmacokinetics of drugs [2]. To date, eleven human OATPs
have been identified, and homologues are found in all mammals, frogs, D. melanogaster and C.
elegans [3,4]. In yeast or bacteria, no homologs are known. Based on multiple sequence align-
ment, the proteins were assigned to the SLC21/SLCO superfamily and grouped in 6 families
further divided in subfamilies [3].
OATPs/Oatps are expressed in the liver, the gastrointestinal tract, the kidney, the blood-brain
barrier and the retina. Some transporters are found in a specific tissue. For instance, OATP1B1
and OATP1B3 are expressed only in the liver. Other OATPs/Oatps are ubiquitously expressed.
In polarized cells, they reside in the basolateral membrane.
The substrate range of OATPs/Oatps is very broad. In general, large amphipathic molecules
are transported. The specificity and transport kinetics of many OATPs/Oatps have been studied
extensively (reviewed by [3,5,6]). Members of the Oatp1 family have a very broad substrate
specificity: In addition to bile salt conjugates, it includes hormones and their conjugates, eico-
sanoids, peptides, various drugs and toxins. Table 3.1 summarizes the compounds transported
by Oatp1a1, Oatp1a4 and Oatp2b1 from rat liver. Oatp1a4 was investigated in this study.
OATPs/Oatps act as anion exchangers. Translocation of the substrates is independent of
the sodium gradient and electroneutral, and it is not clear whether transport is facilitative or
secondary active. Little is known about the mechanistic details of transport. Glutathione and
bicarbonate have been discussed as counterions for Oatp1a1 [7,8], while cis-inhibition or trans-
stimulation of the transport by these ions was not observed for OATP1B1 and OATP1B3 [9]. In
the same study, the electroneutral nature of transport was shown experimentally, thereby demon-
strating the necessity of a counterion. It has been found that a low extracellular pH stimulates
the transport activity and a histidine residue in transmembrane helix 3 has been identified that
serves as a pH sensor [10].
The physiological role of OATPs/Oatps is the clearance of endogeneous and exogeneous
compounds in liver and kidney, and the uptake of substances such as hormone conjugates into
their target tissue. In addition to their role in drug disposition, OATPs/Oatps play a secondary
role in the enterohepatic circulation of bile salts (section 2.1.2) as they contribute to the uptake
of these molecules into hepatocytes.
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Table 3.1: Substrate specificity of Oatps (modified from [1])
Protein
Length
MW
Tissue distribution Substrates
Oatp1a1
670 AA
74.2 kDa
liver, kidney, brain, lung, retina,
skeletal muscle, proximal colon
Bile salts: cholate, glycocholate, tauro-
cholate, TCDCA, TUDCA, sulfotaurolitho-
cholate
Hormones and hormone conjugates: aldos-
terone, cortisol, DHEAS, E217βG, estrone-
3-sulfate, T3, rT3, T4
Peptides: BQ-123, CRC220, deltorphin II,
DPDPE, glutathione
Drugs: dexamethasone, enalapril, fexofe-
nadine, gadoxetate, ouabain, pravastatin,
temocaprilat
Other organic anions: monoglucuronosyl
bilirubin, BSP, BSP-DSP-SG, E3040 glu-
curonide
Organic cations: APD-ajmalinium, N-
methylquinidine, rocuronium
Toxins: ochratoxin A
Oatp1a4
661 AA
liver, kidney, brain, retina Bile salts: cholate, glycocholate, tauro-
cholate, TCDCA, TUDCA
73.3 kDa Hormones and hormone conjugates:
DHEAS, E217βG, estrone-3-sulfate, T3,
T4
Peptides: BQ-123, DPDPE, Leu/enkephalin
Drugs: biotin, digoxin, fexofenadine,
ouabain, pravastatin
Organic anions: APD-ajmalinium, rocuro-
nium
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Oatp2b1 liver, lung, heart, brain, retina Bile salts: taurocholate
682 AA
74.2 kDa
kidney Eicosanoids: LTC4, prostaglandine E1,
prostaglandine E2, prostaglandine D2,
thromboxane B2
Drugs: iloprost
3.1.3 Structural features of OATPs/Oatps
OATPs/Oatps are glycoproteins of about 700 amino acids that share a twelve-transmembrane-
domain topology with cytoplasmic termini, as predicted by hydropathy analysis. Figure 3.1
shows a topology model of Oatp1a4. While the structures of various ABC transporters including
P-glycoprotein were determined by X-ray diffraction [11], experimental structural data is not
available for any member of the SLC21 superfamily. A homology model was suggested by
Meier-Abt et al. [4] based on the crystal structure of lactose permease. The model proposes a
three-dimensional arrangement of the transmembrane helices with the connecting loops omitted.
Lactose permease is a member of the major facilitator superfamily (MFS), one of the largest
families of solute carriers [12]. Although the sequence similarity between OATPs/Oatps and
MFS proteins is rather low, a recent study found indications that a large number of SLC families
including SLC21 share the MFS fold [13].
The most characteristic structural feature found in all members of the SLC21 family is a
large extracellular loop connecting transmembrane helix 9 and 10. This loop is likely to form a
functionally important domain.
3.1.4 The extracellular loop of OATPs/Oatps
The extracellular loop between TM 9 and 10 of OATPs/Oatps comprises about 100 amino acids,
including ten highly conserved cysteines. Hänggi et al. [14] used OATP2B1 to investigate the
role of the domain. OATP2B1∆489−557, a construct lacking the extracellular loop, was mis-
processed and sequestered intracellularly. Individual point mutations of the cysteines to alanine
resulted in reduced surface expression and decreased transport activity. The mutants could be
shown to have a free thiol group, whereas the wild type did not, which led them to argue that all
cysteines are likely to be involved in disulfide bridges. A distant homology to Kazal-type pro-
tease inhibitors has been suggested [1,4]. These small domains containing a short α-helix and a
two-stranded β-sheet form several disulfide bonds. This finding further supports the hypothesis
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Figure 3.1: Topology of Oatp1a4, modified from [1]. The superfamily signature motif D-X-
RW-(I,V)-GAWW-x-G-(F,L) is depicted in yellow. Gray shading shows conserved or similar
positions. Conserved cysteine residues are colored red and their positions are indicated. Poten-
tial glycosylation sites labeled and drawn as trees. Extracellular loop 5 is highlighted.
that OATPs/Oatps contain a disulfide-rich domain. On the other hand, the cysteine pattern might
also be involved in metal binding. Small metal-binding motifs such as zinc fingers often mediate
protein-protein interactions.
3.1.5 Aim of the project
With the long-term goal to provide structural insight into OATPs/Oatps, we aimed to identify
a fragment that would correspond to the extracellular domain of Oatp1a4. A soluble fragment
of the protein would facilitate the elucidation of its structural and functional properties. We
therefore designed and biophysically characterized several constructs of this domain.
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Figure 3.2: Computational models for Oatp1a4: (A) Model of the transmembrane region based
on Escherichia coliEmrD (PDB ID 2GFP [15]). The extracellular domain is not part of the
model. Its position is indicated with an orange sphere. (B) same model as seen from the extra-
cellular side (rotated by 90 degrees towards the reader) (C) model of the extracellular domain of
Oatp1a4 based on the structure of infestin 4 (PDB ID 2ERW [16]).
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3.2 Results
3.2.1 Model of Oatp1a4
We generated a model of Oatp1a4 to guide the design of expression constructs. The algorithm
we used performs a search for the closest homolog with known structure based on the submitted
sequence. For the full-length protein, a model showing the potential arrangement of the twelve
transmembrane helices (Figure 3.2 A, B) is produced with the structure of the multidrug efflux
protein EmrD from Escherichia coli [15] as a template. Similar models are obtained based on the
structures of glycerol-3-phosphate transporter (GlpT) or lactose permease (LacY). All template
proteins contain twelve transmembrane helices and belong to the major facilitator superfamily
(MFS). The suggested structure corresponds to the previously published model of OATP1B3 [4]
except that the position of TM1 and TM2 is swapped. In addition, our model includes most
loops, which were omitted previously. The long intracellular connection between TM6 and
TM7 lines the cytoplasmic part of the transporter.
However, the model lacks the residues representing the extracellular domain, located be-
tween TM9 and TM10. Hence, we submitted the corresponding sequence to the structure pre-
diction server and obtained a model based on the crystal structure of the factor XIIa inhibitor
infestin 4 [16], a serine protease inhibitor with a Kazal-type fold. The 48-residue model contains
eight cysteines and suggests three disulfide bonds between residues 442 and 468, 444 and 464
as well as 453 and 485 (Figure 3.2 C).
3.2.2 Construct design
The design of constructs for the soluble expression of a fragment of Oatp1a4 was based on
the hypothesis that extracellular loop 5 folds into a disulfide-rich domain homologous to Kazal
type II serine protease inhibitors. Domain boundaries for our constructs were designed based
on an alignment of six OATPs/Oatps taking into account the degree of conservation. We also
aligned the sequences with porcine pancreatic trypsin inhibitor (Figure 3.3). Three constructs of
different length were defined as follows: 10C corresponds to residues 414 to 505 of Oatp1a4,
containing 92 amino acids and all ten conserved cysteines of the extracellular loop. 8C includes
residues 414 to 485 (72 amino acids), whereas short consists of residues 436 to 485 of Oatp1a4
(50 amino acids). The latter two constructs have eight cysteines.
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o^^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^o^
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Oatp1a4 LAFWLCLSEYLLSFLSYVMTCDNFPVAGLTTSYEGVQHQLYVENKVLADCNTRCN.CSTNTWDPVCGDNG.LAYMSACLAGCE....KSVGTGTNMV 479
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OATP1A2 FQNCSCIQTSG....NSSAVLGLCDKGPDCSLMLQYFLILSAMSSFIYSLAAIPGYMVLL 536
OATP1B1 FYNCSCLEVTGLQNRNYSAHLGECPRDDACTRKFYFFVAIQVLNLFFSALGGTSHVMLIV 560
OATP1B3 FYNCSCVEVTGLQNRNYSAHLGECPRDNTCTRKFFIYVAIQVINSLFSATGGTTFILLTV 560
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Figure 3.3: ClustalW multiple alignment from TM9 to TM10 of six Oatps/OATPs with porcine
pancreatic trypsin inhibitor. The domain boundaries of the three constructs 10C, 8C and short
are indicated with bars below the alignment.
3.2.3 Soluble expression of the domain as a fusion protein
The three constructs were cloned into a variety of expression vectors summarized in Table 3.2.
The three constructs 10C, 8C and short behaved very similarly with regards to expression in a
given vector system. Since the extracellular domain of Oatp1a4 contains many cysteines, we
first aimed at secreting the protein into the periplasm of E. coli in order to allow disulfide bond
formation in an oxidizing environment. To this end, we tested a set of vectors containing a
pelB leader peptide. A low level of expression was achieved only when the protein was fused
to maltose binding protein (MBP). However, when using the pMAL vector system, the protein
formed soluble aggregates and the fusion protein could not be cleaved proteolytically. In con-
trast, cytoplasmic production using a pET vector lead to high expression levels of the protein
fused to NusA, thioredoxin, GB1 or MBP (Table 3.2). We used the construct for the cytoplas-
mic expression of the domain as an N-terminal fusion with MBP from a pET vector for further
experiments. An additional construct was made in which the MBP-fusion protein is modified by
a C-terminal Strep-tag.
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Table 3.2: Vectors for the expression of the extracellular domain of Oatp1a4.
Vector N-term. tag Cleavage site C-term. tag expression
pET20b(+) pelB His no expression
pMAL-pm1 pelB-MBP Prescission detectable
pMAL-pm1 pelB-MBP Prescission His detectable
pGEX-6P1 GST Prescission no expression
pMAL-c2E MBP Ek no expression
pETM80 periplasmic DsbC TEV no expression
pETM82 cytoplasmic DsbC TEV no expression
pETNus-1a 6xHis-NusA TEV expressed
pETTrx-1a 6xHis-thioredoxin TEV highly expressed
pETGB1-1a 6xHis-GB1 TEV highly expressed
pETMBP-1a 6xHis-MBP TEV highly expressed
pETMBP-1a 6xHis-MBP TEV Strep highly expressed
A B
MBP
MBP-10C MBP-short
MBP
MM
50 kDa
40 kDa
50 kDa
40 kDa
1 2 3 4 1 2 3 4
Figure 3.4: Purification of the extracellular domain fused to MBP. 12 % SDS PAGE of A) MBP-
10C or B) MBP-short. Lane M) Size marker, 1) cell lysate, 2) flow-through IMAC, 3) elution
IMAC, 4) TEV digest.
3.2.4 Properties of the purified extracellular loop
Purification of the fusion protein
Optimal expression of the domain with MBP fused to its N-terminus was obtained using LB
medium after induction with 1 mM IPTG over night at 18 degrees. The cells were collected and
lysed mechanically. The extracellular loop contains many cysteines that are kept reduced in the
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cytoplasm where the protein was produced. It proved to be crucial to include reducing agents in
the lysis buffer to prevent protein precipitation upon exposure to oxygen. Both 1 mM DTT or a
combination of 3 mM oxidized glutathion and 0.3 mM reduced glutathion were possible.
After lysis, the protein was purified via its His-tag. Alternatively, the MBP fusion protein
could be purified by amylose affinity chromatography. While both methods yielded fusion pro-
tein of high purity, the Ni2+-NTA agarose used for affinity purification via the His-tag was not
compatible with DTT. Figure 3.4 shows a typical SDS-PAGE analysis of the affinity purification
of MBP-10C and MBP-short.At this stage of purification, the yield from 1 l of expression culture
was typically around 100 mg.
Aggregation behaviour of the fusion proteins
The aggregation behaviour of the fusion protein in various buffers was judged by gel filtration
and is summarized in Table 3.3. Soluble aggregates were observed for MBP-10C and MBP-8C in
50 mM Tris/HCl pH 8, 150 mM NaCl without additives and in presence of various redox buffers
such as different ratios of oxidized and reduced glutathion, L-cysteine and L-cystine, or DTT.
The C-terminal Strep-tag also led to aggregation of the fusion protein. In general, MBP-10C
and MBP-8C behaved similarly. In contrast, MBP-short existed in a monomer-dimer equilib-
rium when gel-filtrated in 50 mM Tris/HCl pH 8, 150 mM NaCl with or without added reducing
agent. Under the same conditions, MBP isolated after cleavage of the fusion protein eluted
in a single monomeric peak (Figure 3.5). Therefore, we conclude that the oligomerization be-
haviour was induced by short. We analyzed the fractions from the two peaks of MBP-short using
non-reducing SDS PAGE. The dimer peak contains covalently linked and non-covalently linked
MBP-short even in presence of 1 mM DTT. A smaller fraction of covalent higher-molecular-
weight oligomers elutes in a shoulder. The presence of intermolecular links is an indication that
the disulfide bonds are not formed correctly or completely upon oxidation of the protein.
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Table 3.3: Aggregation behaviour of the fusion protein as judged by gel filtration in 50 mM
Tris/HCl pH 8.0, 150 mM NaCl with the indicated additives. n.d. not determined
Condition MBP-10C or MBP-8C MBP-short
no additives aggregation monomer-dimer equilibrium
1 mM DTT aggregation monomer-dimer equilibrium
3 mM GSH, 0.3 mM GSSG aggregation monomer-dimer equilibrium
3 mM GSH, 1 mM GSSG aggregation n.d.
5 mM L-cysteine, 0.5 mM L-cystine aggregation n.d.
500 mM NaCl aggregation n.d.
0.2 % tween-20 aggregation n.d.
Strep-tag aggregation aggregation
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Figure 3.5: Gel filtration profile of MBP-10C, MBP-short and MBP in 50 mM Tris/HCl pH 8.0,
150 mM NaCl, 1 mM DTT using a Superdex 200 column. The fusion protein exists in a
monomer-dimer equilibrium, while MBP elutes in a monomeric peak. The indicated fractions
of MBP-short were analyzed using SDS PAGE under non-reducing conditions.
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Cleavage and isolation of the domain
All constructs used for expression contained a cleavage site for tobacco etch virus (TEV) pro-
tease at the N-terminus of the domain. After enzymatic cleavage, the fusion partner was re-
moved via its N-terminal His-tag, while the domain was recovered with the flow-through. For
constructs modified with a C-terminal Strep-tag, the domain could alternatively be captured by
affinity chromatography using a streptavidin-coupled matrix. Since MBP-10C was prone to ag-
gregation, proteolytic cleavage was not complete. About 50 % of the fusion protein was cleaved
as judged by comparison of the intensity of the bands for MBP-10C and MBP when analyzed by
SDS-PAGE (Figure 3.4 A). In contrast, MBP-short, which does not form high-molecular weight
aggregates, is cleaved almost completely (Figure 3.4 B). Due to its small size, the domain could
only be visualized by Coomassie staining when high amounts of protein were used for SDS-
PAGE. Figure 3.4 C shows that the isolated domain was highly pure. Under non-reducing con-
ditions, the domain migrates further during SDS-PAGE than under reducing conditions. This
observation indicates that the domain is more compact in an oxidizing environment due to the
presence of disulfide bonds. The typical yield from 1 l of expression culture was 1.5 mg.
Size exclusion chromatography was used as a polishing step and to judge the monodispersity
of the protein. 10C elutes mainly in the void volume of a Superdex 75 column, while short is
found in two main peaks at 12 and 14 ml elution volume. Suspecting that the aggregation
behaviour is caused by incorrect formation of disulfide bonds, we used an approach to allow the
protein to form the native interactions by dialysis in a redox buffer in presence of zinc. This
would also enable the reconstitution of potential zinc-binding motifs. This disulfide shuffling
protocol does not affect the properties of 10C. In short, however, the 12 ml peak significantly
decreases in favour of the 14 ml peak.
The oligomeric state of the protein from the peak fraction at 14 ml was investigated in a sed-
imentation velocity analytical ultracentrifugation experiment. The analysis of the data showed a
single species with a molecular mass of 7700 ± 1600 Da (Figure 3.7), which corresponds well
to the theoretical mass of the short monomer of 6020.4 Da. The frictional ratio was fit to 1.29,
which is a common value usually observed for globular proteins. The quality of the fit is high
with a RMSD of 0.0076. We conclude that the 14 ml peak during size exclusion chromatography
using a Superdex 75 column represents the monomer of purified short and used this fraction for
all experiments described below.
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Figure 3.6: Gel filtration profile of (A) 10C or (B) short with or without disulfide shuffling in
50 mM Tris pH 8.0, 150 mM NaCl using a Superdex 75 column. (C) 15 % Schägger gel of
purified 8C-Strep: M) Molecular weight marker 1) purified 8C-Strep under reducing conditions
2) purified 8C-Strep under non-reducing conditions. conditions.
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Figure 3.7: Sedfit analysis of sedimentation velocity analytical ultracentrifugation data for short.
The absorption at 280 nm was monitored during centrifugation at 42000 rpm. The top panel
shows the raw data. The residuals plotted in the middle panel indicate a good quality of the fit.
The resulting mass is a single species with a molecular mass around 8000 Da.
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Formation of disulfide bonds
In an effort to assess how many cysteine residues in the purified fragments are involved in disul-
fide bonds, free thiols were quantified using Ellman’s reagent dithionitrobenzoic acid (DTNB).
Each of the three fragments of Oatp1a4 had two free mercaptogroups. It is important to note that
this value represents the average number of free thiols per molecule. The result was the same
both under native and denaturing conditions, meaning that the free cysteines are accessible on
the surface, thereby explaining the potential for intermolecular disulfide crosslinks.
We used the short construct in an attempt to identify these free cysteines. To this end, the
protein was carbamidomethylated using iodoacetamide. The modification sites were then to be
identified with ESI-MS. The unmodified domain has a mass of 6013.4 Da (Figure 3.8 A), while
the predicted mass of short is 6020.4 Da. This finding agrees well with the observation that most
cysteines are oxidized, since the formation of a disulfide bond results in a mass difference of
2 Da. When subjecting the domain to HPLC using a H2O/acetonitrile gradient on a C8 column
after treatment with iodoacetamide, the protein elutes in a broad peak at a retention time of
19-25 min (Figure 3.8 B). ESI-MS of the peak fraction shows a number of peaks with a mass
difference of 56 Da (Figure 3.8 C), revealing that the sample contains unmodified short as well
as protein modified with one, two, three, four or five carbamidomethyl groups. When the sample
is reduced, the peaks corresponding to the domain with a different number of modifications can
be recognized, but not seperated during HPLC. ESI-MS of the indicated fraction still shows
a distribution of masses representing the domain with various numbers of carbamidomethyl
groups (Figure 3.8 D). These results suggest that short does not have a defined structure, but
forms disulfide bonds randomly when exposed to oxygen during lysis.
Random coil structure of the fragments
Since experiments described above suggested that the domain might be unstructured, we recorded
CD spectra of both purified 10C and short in order to estimate the secondary structure content
of the domain. In parallel, we wanted to investigate the effect of disulfide shuffling, as this treat-
ment resulted in a different behaviour of the domain during gel filtration. The purified sample
was devided in two parts. One part was left untreated, while the other was dialyzed in a redox
buffer in presence of zinc to allow shuffling of erroneous disulfide bonds prior to the measure-
ment. The absorption of polarized light was recorded from 250 to 190 nm for both constructs
before or after redox shuffling (Figure 3.9). The secondary structure content was then estimated
using SOM-CD (Table 3.4). While 10C contains 20 % alpha-helical and 40 % beta-sheet struc-
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Figure 3.8: Analysis of carbamidomethylated short using HPLC and ESI-MS: (A) ESI-MS of
purified short (B) HPLC of carbamidomethylated short before (blue) and after reduction (red).
Fractions analyzed by ESI-MS are indicated by arrows in the respective color. (C) ESI-MS
of carbamidomethylated short fractionated by HPLC (D) ESI-MS of carbamidomethylated and
reduced short after fractionation by HPLC
ture, the CD spectrum of short indicates a random coil. Disulfide shuffling does not affect the
secondary structure content of either domain. We conclude that the domain is not in its native
state.
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Figure 3.9: Circular dichroism spectra of A) 10C B) 10C after disulfide shuffling C) short D)
short after disulfide shuffling. The spectra were recorded in 10 mM Tris/boric acid pH 8 at 4
degrees. The molar ellipticity is plotted versus the wavelength from 250 to 190 nm.
Table 3.4: Secondary structure content of domain estimated by SOM-CD
Construct alpha (%) beta (%) turn (%) random (%)
10C 20.2±9.9 41.5±4.4 9.8±1.2 28.5±4.8
10C after disulfide shuffling 20.2±9.9 41.5±4.4 9.8±1.2 28.5±4.8
short 1.3±4.5 2.6±9.1 1.1±4.0 95.0±17.6
short after disulfide shuffling 1.2±4.4 2.4±8.8 1.1±3.9 95.3±17.1
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Figure 3.10: A) 1H NMR spectrum of short at 280 K B) zoom on the amide region from 6.3 to
10.2 ppm at 280 K (top panel) or 300 K (bottom panel).
To investigate whether the domain is structured with an independent method, we recorded a
1D 1H NMR spectrum of purified short at 280 K and 300 K (Figure 3.10). Random coil chemical
shifts for main chain amide protons are typically observed at 8.1-8.8 ppm [17]. For a structured
domain we would expect conformation-dependent chemical shift dispersion of the signals from
backbone amide protons of folded regions above 8.5 ppm. However, the observed chemical
shifts are typical for a random coil structure, showing only little dispersion in this region. An
increase of temperature from 280 K to 300 K did not result in sharpening of the peaks, which is
another indication for an unstructured protein sample.
60 CHAPTER 3. THE EXTRACELLULAR LOOP OF OATP1A4
3.3 Discussion
Due to the central role of transport proteins in drug absorption, distribution and extrusion, there is
high interest in the study of the interaction of a potential therapeutic with the transporter. Organic
anion transporting polypeptides (OATPs/Oatps) are important determinants of the bioavailability
of drugs. Structural information on this protein class would therefore be of high value. One
characteristic feature is the highly conserved extracellular loop 5 which connects transmembrane
helices IX and X.
Aiming to produce a soluble domain using a bacterial expression system, we designed and
analyzed constructs that correspond to the extracellular loop 5 of Oatp1a4 from Rattus norvegi-
cus. We successfully expressed several fragments in high amounts in the cytoplasm of E. coli
as a fusion protein with MBP that we purified to homogeneity. While longer constructs were
polydisperse and aggregation-prone even in presence of the fusion partner, the shortest construct
existed in an equilibrium between the monomer and a partly covalent dimer. Intramolecular
crosslinking was observed even in presence of reducing agents. Due to its relatively large size,
the fusion partner MBP likely prevented intermolecular disulfide bonds between more than two
molecules.
Following cleavage of the fusion protein, we were able to isolate high amounts of the pure
fragment. Longer constructs were highly aggregated, but seemed to contain secondary structure
elements. In contrast, while the shortest construct was soluble, it had a random coil structure.
Most cysteines were involved in disulfide bonds, but these covalent links did not follow a defined
pattern. In place of a natively structured domain, the isolated protein consisted of a distribution
of conformations with different non-native disulfide patterns as demonstrated by mass spectrom-
etry following the modification of free cysteines.
The results suggest that the domain boundaries were not chosen correctly. The construct
design had been based on the proposed homology of the extracellular loop of OATPs/Oatps to
Kazal-type serine protease inhibitors [1,4]. Although this assumption is widely accepted in the
field, the prediction of the fold of an extracellular domain of OATPs/Oatps might be biased by
the occurence of a large number of cysteines leading to low complexity of the sequence. The
neighboring extracellular loop 6 also contain several cysteine residues that may be in the vicinity
of thiols in extracellular loop 5. Disulfide bonds between these residues may be present in the
native structure of OATPs/Oatps. This hypothesis could be tested with a set of double mutants
by detecting free cysteines with a sulfhydryl-reactive agent.
Cysteine-rich domains are common in cell-surface proteins. One example is the scavenger
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receptor cysteine-rich domain (SCRD), which is found at the extracellular C-terminus of scav-
enger receptors, but also in other cell surface proteins of immune cells [18]. The structures of
several SRCR domains are known (e. g. [19] and show the presence of three disulfide bonds.
Additional cysteines can be present that can be involved in chelating divalent cations, as ob-
served for the SRCR domain of the macrophage receptor MARCO [20]. The domain mediates
receptor-ligand interactions by domain swapping.
It is well known that cysteines do not exclusively form disulfide bonds, but may provide
metal binding sites. Metal binding motifs such as zinc fingers are highly in soluble proteins,
playing an important role in the interaction with DNA, but also in mediating protein-protein
interaction [21]. Although the oligomeric state of OATPs/Oatps is not known, cross-linking
experiments showed that the transporters are partly present in form of non-covalent dimers on
the cell surface [14]. Metal-binding motifs are also known in membrane proteins: Cysteine-
loop receptors such as the pentameric contain a low-affinity and a high-affinity regulatory zinc
binding site located in a loop at the interface between the transmembrane part and the soluble
domain of the protein.
A previous study showed that substitution of each of the cysteines of the extracellular loop
5 with alanine resulted in a free thiol group that could be detected with a sulfhydryl-reactive
reagent [14]. This observation suggests that all cysteines are involved in disulfide bonds. How-
ever, a metal ion bound with high affinity would also shield cysteines from thiol-reactive agents.
As long as a soluble domain cannot be produced that adopts the native conformation of
the extracellular loop 5 in OATPs/Oatps, we have to rely on information from the full-length
protein. Assays to measure uptake of [3H]-labeled substrate into CHO cells stably transfected
with OATPs/Oatps are established [22]. We performed initial experiments to investigate the
effect of zinc or chelating agents on the transport activity of rat liver Oatps. Here, conditions
need to be found that do not affect the viability of the cells.
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3.4 Experimental procedures
Materials used for this project are listed in the appendix.
3.4.1 Protein structure prediction
The homology models of Oatp1a4 and the extracellular loop were generated by submitting the
sequence of the full-length protein as well as residues 410-507, which correspond to the extracel-
lular loop 5, to the structure prediction program Phyre [23]. This algorithm uses profile-profile
matching based on predicted secondary structure to build a three-dimensional model.
3.4.2 Cloning of the extracellular loop of Oatp1a4
The DNA sequence of the extracellular loop corresponding to residues 414 to 505, 414 to 485
or 436 to 485 of Oatp1a4 was amplified by PCR from the template pSPORT-Oatp1a4 [24] to
yield the constructs 10C, 8C or short, respectively. The resulting products were cloned into
pET20b(+), pMAL-pm1, pMAL-c2E pGEX-6P1, pETM80, pETM82, pETNus-1a, pETTrx/1a,
pETGB1-1a and pETMBP-1a. Constructs in pET20b(+), pMAL-pm1 and pETM80 were de-
signed for secretion to the periplasm, whereas the other constructs were for protein expression
in the cytoplasm. The described expression vectors allowed the screening of various N-terminal
fusions of the constructs with solubility enhancers such as MBP, GST, GB1, thioredoxin or
NusA. All N-terminal tags were followed by a sequence encoding for a specific cleavage site for
Prescission, enterokinase or tobacco etch virus (TEV) protease.
3.4.3 Expression and purification of the domain
Small-scale expression tests
Expression tests were performed in 5 ml cultures in LB medium. A single colony of Escherichia
coli BL21(DE3) freshly transformed with the expression vector was used to inoculate 5 ml LB
containing 100 µg/ml ampicillin or 50 µg/ml kanamycin. The starter culture was incubated over
night at 37 degrees and 230 rpm. The next morning, 100 µl of the stationary culture were used
to inoculate 5 ml fresh medium. Expression was induced at OD600 = 0.5 by addition of IPTG
to 1 mM for 3 hours at 37 degrees and 230 rpm or at 18 degrees overnight at 230 rpm. Samples
were taken before and after induction and analyzed by SDS PAGE.
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Expression and purification of the MBP fusion protein
MBP-10C, MBP-8C or MBP-short with or without C-terminal Strep-tag were expressed from
pETMBP-1a. A single colony of Escherichia coli strain BL21(DE3) freshly transformed with
the expression vector was used to inoculate 5 ml LB containing 50 µg/ml kanamycin. The starter
culture was grown over night at 37 degrees and 230 rpm. The next day,500 ml of LB containing
50 µg/ml kanamycin in a 2 l baffled flask were inoculated with the starter culture and incubated
at 37 degrees and 110 rpm. Expression was induced at OD600 = 0.8 with 1 mM IPTG over night
at 18 degrees. After harvesting the cells by centrifugation for 15 min at 4000 rpm and 4 degrees,
the cell pellets were flash-frozen in liquid nitrogen and stored at -80 degrees until use.
For purification, we typically used cells from 1 l of expression culture. The pellets were
thawed on ice in 20 ml lysis buffer (50 mM Tris/HCl pH 8.0, 150 mM NaCl, 3 mM GSH,
3 mM GSSG, 0.1 mg/ml DNAseI or 50 mM Tris/HCl pH 8.0, 150 mM NaCl, 1 mM DTT,
0.1 mg/ml DNAseI). The cells were disrupted mechanically by three rounds of French press at
4 degrees. After removing cell debris by centrifugation for 20 min at 5000 rmp and 4 degrees,
the supernatant was subjected to affinity chromatography using Ni-NTA agarose (Qiagen) or
amylose resin (New England Biolabs).
To isolate the domain, the purified fusion protein was cleaved using 10 µg of tobacco etch
virus (TEV) protease per mg of protein during dialysis in 50 mM Tris pH 8.0, 150 mM NaCl,
3 mM GSH, 0.3 mM GSSG (or 1 mM DTT) over night at 4 degrees. The domain was isolated
via its C-terminal Strep-tag during affinity chromatography using StepTactin (IBA Biotech) or
by passing the mixture three times over a Ni-NTA column equilibrated with 50 mM Tris pH 8.0,
150 mM NaCl, 10 mM imidazol. The domain is recovered from the flow-through, while the
His-tagged fusion partner, uncleaved protein and the protease are bound to the column material.
3.4.4 Size exclusion chromatography
Size exclusion chromatography was used as a polishing step following purification, but also to
judge the monodispersity of the protein preparation. The fusion protein was analyzed using a Su-
perdex 200 10/300 GL column (GE Healthcare), while preparative and analytical gel filtrations
were performed on a Superdex 75 10/300 GL column (GE Healthcare).
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3.4.5 Ellman assay
The reaction of dithionitrobenzoic acid (DTNB) with accessible thiols goes along with the stoi-
chiometric release of a nitrothiobenzoate anion. The yellow compound can easily be quantified
by absorption spectroscopy. The so-called Ellman’s reagent is commonly used to determine the
number of free cysteines in a protein sample.
We used N-acetylcysteine to prepare a standard curve. Triplicates of 1 ml samples of 0, 5, 10,
15, 20, 30, 40 and 50 /muM N-acetylcysteine in the reaction buffer (50 mM Tris/HCl pH 8.0,
150 mM NaCl, 1 mM EDTA) were mixed with 50 µl of 3 mM DTNB and incubated at 37 degrees
for 30 min. The absorbance was then measured at 412 nm in a spectrometer using the buffer
as a reference. The concentration of N-acetylcysteine was plotted versus the average absorption
value and a linear curve fit was applied. To determine the number of free cysteines in the native
sample, 200 µl of the protein solution with known concentration (5-10 µM) was diluted 1:5
in the reaction buffer. After addition of 50 µl 3 mM DTNB, the samples were incubated for
30 min at 37 degrees and the absorption was measured at 412 nm. For the denatured sample,
the procedure was repeated diluting the protein in 8 M urea in reaction buffer. To quantify the
total number of cysteines, 100 µl of the protein solution were diluted 1:5 in 125 mM DTT, 8 M
urea in reaction buffer and reduced for 30 min at 30 degrees. DTT was then removed by buffer
exchange using a NAP-5 column equilibrated with 6.4 M urea in reaction buffer. 1 ml of the
eluate was mixed with 50 µl of 3 mM DTNB after determination of the protein concentration.
After incubation for 30 min at 37 degrees, the absorbance at 412 nm was determined. The
respective number of cysteines per molecule was calculated using the standard curve.
3.4.6 Modification of free cysteines
Iodoacetamide is a nucleophile that reacts with free cysteines, resulting in the modification of
the side chain with a carbamidomethyl group. We treated purified short with iodoacetamide
to identify cysteine residues not involved in disulfide bonds. To this end, 0.5 volume of 1 M
iodoacetamide was added to purified and concentrated short (3-4 mg/ml). After allowing the
reaction to proceed for 30 min at room temperature in the dark, the reaction was quenched by
adding 1/100 volume of 10 % trifluoroacetic acid (TFA). The sample was analyzed by HPLC
using a C8 column with a H2O/acetonitrile gradient. Fractions were collected manually and
analyzed by ESI-MS using the service of the Functional Genomics Center Zurich. For reduction
of disulfide bonds, fractions were lyophilized, resuspended in 100 µl 50 mM Tris/HCl pH 8.0,
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150 mM NaCl and mixed with 50 µl of 1 M DTT. After incubation at room temperature for 3 h,
100 µl were used for HPLC analysis and subsequent ESI-MS.
3.4.7 Analytical ultracentrifugation
Sedimentation velocity analytical ultracentrifugation to determine the oligomeric state of the
purified domain were performed in an Optima XL-1 centrifuge (Beckman Coulter) with a Ti50
rotor using epoxy counter pieces with sapphire windows. After gel filtration, the protein sample
with A280 ≈ 1 was filled in the sample chamber, while the reference cell was loaded with gel
filtration buffer. The absorption at 280 nm was measured during centrifugation at 42000 rpm at
20 degrees. The data were analyzed using Sedfit [25].
3.4.8 Circular dichroism
We recorded circular dichroism (CD) spectra using a Jasco-715 spectrometer (Jasco, Japan).
The protein sample was dialyzed three times in 50 volumes of 10 mM Tris/boric acid pH 8 at
4 degrees. For the measurement, the protein was diluted to 10 µM and filled into a cuvette
with a path length of 1 mm. The CD signal in mdeg was scanned from 250 to 190 nm in
1 nm increments. After substraction of the reference sample, the signal was converted to molar
ellipticity and the secondary structure content was estimated using SOM-CD [26].
3.4.9 NMR
Nuclear magnetic resonance (NMR) was carried out by Prof. Oliver Zerbe at the Department of
Organic Chemistry of the University of Zurich in order to judge whether short forms a structured
domain. One-dimensional 1H NMR spectra of 500 µM purified short in 20 mM Tris/HCl pH 8.0,
50 mM NaCl were recorded at 280 K and 300 K.
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4.1 Abstract
The formation of well-diffracting crystals is a major bottleneck in structural analysis of mem-
brane proteins by X-ray crystallography. One approach to improve crystal quality is the use of
DARPins as crystallization chaperones. Here, we present a detailed analysis of the interaction
between DARPins and the integral membrane protein AcrB. We find that binders selected in
vitro by ribosome display share a common epitope. The comparative analysis of three crystal
structures of AcrB-DARPin complexes allowed us to study the plasticity of the interaction with
this dominant binding site. Seemingly redundant AcrB-DARPin crystals show substantially dif-
ferent diffraction quality as a result of subtle differences in the binding geometry. This work
exemplifies the importance to screen a number of crystallization chaperones to obtain optimal
diffraction data. Crystallographic analysis is complemented by biophysical characterization of
nine AcrB binders. We observe that small variations in the interface can lead to differing behav-
ior of the DARPins with regards to affinity, stoichiometry of the complexes and specificity for
their target.
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4.2 Introduction
While membrane proteins are important drug targets, high-resolution structural information on
this protein class is still difficult to obtain. In the solubilized state, the detergent micelle shields
the hydrophobic surface of the protein that would naturally be embedded in the membrane.
This area is therefore not amenable to forming crystal contacts. The hydrophilic surface of
a membrane protein, often consisting of loops connecting the membrane-spanning secondary
structure elements, is comparatively small. One strategy to mediate crystal contacts is the use of
soluble binding proteins to provide a larger surface for intermolecular interaction.
An additional complication is that transporters and receptors require intrinsic flexibility to
carry out their function. Conformational heterogeneity, however, is not favorable for crystal-
lization as it increases the entropic cost of lattice formation. Stabilization of a dynamic part
of the crystallization target or shifting a thermodynamic equilibrium to one conformation can
be achieved by a ligand or inhibitor. A prominent example is the use of vanadate to trap ABC
transporters in a nucleotide-bound conformation [1]. Natural or designed proteinaceous binding
partners are an attractive alternative.
Traditionally, antibody fragments were used to improve the quality of membrane protein
crystals [2]. One example is the potassium channel KcsA crystallized in complex with Fab
fragments [3], yielding a structure at 2 Å resolution as compared to 2.8 Å without crystallization
chaperone. The antibody fragment mediates all crystal contacts and could be used for phasing
by molecular replacement. In addition to antibody-based binding proteins, alternative scaffolds
have become more widely used [4].
Designed ankyrin repeat proteins (DARPins) are modular proteins for the evolutionary de-
sign of protein binders [5]. Structurally, a repeat is composed of an alpha-turn-alpha motif
followed by a loop that connects to the next repeat [5,6]. The signature motif TPLH contains a
proline preceding the first helix which induces a kink at the transition from the loop to the helix,
resulting in an overall L-shape of the module. The lateral surfaces of the repeats are hydropho-
bic, allowing the assembly of the modules in a stacking mode. Internal repeats are based on a
consensus sequence, and are flanked by an N-terminal and a C-terminal capping module with a
charged surface, thus preventing aggregation. As for the nomenclature, NxC is a DARPin with
x internal repeats flanked by the terminal caps.
Libraries have been constructed based on the 33 amino acid consensus design [5]. Six
residues in the potential protein-protein interaction interface are allowed to be any amino acid
except glycine, proline or cysteine. An additional degenerated codon allows for the incorpora-
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Figure 4.1: (A) Resolution of AcrB structures in space groups P212121, C2, P1 and R32 pub-
lished in the PDB (B) Packing of AcrB crystals: In space groups P212121 and C2, there is one
AcrB trimer or AcrB-DARPin complex in the asymmetric unit, while in case of P1, there are
two trimers per asymmetric unit. The subunits of AcrB are shown in green, yellow and blue.
DARPins are colored red. In the crystal form with space group R32, the protomers of the AcrB
trimer (green) are related by crystallographic symmetry. The area marked with a red box is
shown in detail in Figure 4.6.
tion of asparagines, tyrosine or histidine at position 26, the last residue of the second helix. In
an N3C format containing three internal repeats flanked by capping modules, this randomization
results in a theoretical diversity of 3.8 · 1023. In contrast to antibodies and antibody fragments,
DARPins are cysteine-free proteins characterized by extraordinary thermodynamic and chemical
stability as well as high expression yields [5].
Ribosome display [7] and phage display [8] have been successfully used to select binders to
a variety of protein targets including membrane proteins [9–11], and structures of many of the
resulting complexes proof the suitability of DARPins as crystallization chaperones [10,12–18].
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The first membrane protein target that yielded a crystal structure in complex with a DARPin
crystallization chaperone is AcrB from Escherichia coli. AcrB belongs to the superfamily of
RND (resistance/nodulation/cell division) transporters [19] and is the inner-membrane compo-
nent of the AcrAB-TolC multidrug efflux system. The proton-driven transporter has been ex-
tensively characterized on a genetic, structural and functional level [20]. To date, 26 crystal
structures of the protein have been deposited to the PDB (Figure 4.1 A). The first structure was
solved in space group R32 and showed a symmetric conformation of the homotrimer with the
three-fold symmetry axis relating the protomers [21]. The best resolution that could be obtained
in this crystal form was 2.7 Å [22]. Later, AcrB was crystallized in an asymmetric form in space
groups C2, P1 [23,24] and, in complex with DARPin binders, in P212121 [16]. Crystallization
in space group P212121 was possible due to a crystal contact mediated by a DARPin binding
specifically to AcrB. Two DARPins were bound to the AcrB trimer, underlining the asymmetry
of the molecule.
In AcrB crystals in space groups P1, C2 or R32, crystal contacts are formed between the
periplasmic domains or between the cytoplasmic loops connecting the transmembrane helices.
This results in a layer-like crystal packing. In many membrane protein crystals, the lattice is
built up in layers with weak interactions in one dimension, leading to anisotropic diffraction data
and high mosaicity, although these problems did not occur with AcrB crystals. In contrast, the
DARPin-mediated crystal lattice provides equal contacts in all three dimensions (Figure 4.1 B).
The resulting resolution of 2.5 Å is the highest so far reported for AcrB, which is a consequence
of the improved crystal packing mediated by DARPin binders.
The asymmetric structures provided insight into the transport mode, representing a snapshot
of three conformations adopted by the protomers during the transport cycle: the access (loose)
conformation, binding (tight) conformation and the extrusion (open) conformation. Possible
drug extrusion pathways were identified [16] and a rotary pump mechanism was suggested [16,
23,24], a hypothesis that was later confirmed by cross-linking experiments [25].
Here, we describe the in-depth analysis of the pool of DARPin binders specific for AcrB
selected in vitro by ribosome display. When mapping the binding sites on AcrB, we found that
all DARPins bind to an overlapping epitope. Comparing three crystal structures of AcrB in
complex with different DARPin binders allowed us to study the plasticity of the protein-protein
interaction and to evaluate the effectiveness of those DARPins as crystallization chaperones. We
also compared affinities, determined the stoichiometry of the complexes and investigated the
specificity for AcrB.
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4.3 Results
4.3.1 Characterization of DARPin binders
Epitope mapping
Our study aims at the characterization of DARPin binders to AcrB after ribosome display selec-
tion [16]. We used ELISA techniques to map the binding sites of various DARPins on AcrB.
In order to identify alternative binders from the pool after selection round 3 and 4, 198 clones
of each round were tested, comparing the signal representing the interaction of the DARPin
with biotinylated AcrB in absence and presence of competing AcrB or the previously described
binder 1108_19 [16]. In the following, the latter will be referred to as DARPin#1. We identified
23 specific binders from round 3 and 69 specific binders from round 4, corresponding to a three-
fold enrichment. However, all DARPins were competed by DARPin#1. We conclude that they
bind to an overlapping epitope on AcrB.
Eight DARPin binders from the fourth selection round, in the following referred to as
DARPin#2 to DARPin#9, were chosen for further characterization. Figure 4.2 shows the com-
petition ELISA results for these binders. The signal resulting from the interaction of AcrB with
DARPin#1 is reduced to background level when competing with any of the binders DARPin#1-
#9, while the non-specific DARPin E3_5 [5] does not have an effect on the signal (Figure 4.2
B). All binders therefore interact with an overlapping epitope. In the reverse experiment, we
immobilized DARPin#1-#9 and used DARPin#1 as competitor (Figure 4.2 C). Also here, we
observed a significant reduction of the signals. The signal from AcrB binding to DARPin#2 is
not reduced as efficiently due to the high affinity of this binder.
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Figure 4.2: Competition ELISA to map binding sites of DARPins on AcrB: (A) Experimental
setup: DARPins fused to a C-terminal myc-tag were immobilized via α-myc IgG. Binding of
biotinylated AcrB was detected with a streptavidin-alkaline phosphatase conjugate. Competi-
tor (untagged DARPin or unbiotinylated AcrB) was used at a concentration of 1 mM (20-fold
excess). (B) Competition of AcrB binding to DARPin#1. (A) and (B) The ELISA signal with-
out competition (white bar) is compared to the signal in presence of a competitor (blue bars).
Controls marked with asterisk include competition with the non-specific DARPin E3_5, and
competition with AcrB or DARPin#1.
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Sequences: Conserved features of DARPin binders
Figure 4.3 shows an alignment of the amino acid sequences with the N3C sequence. DARPins
#2-#8 differ from DARPin#1 in 15 to 18 positions. Despite the considerable sequence variation,
these binders share several common features with DARPin#1. In the first internal repeat of
DARPins #2-#8, we find predominantly hydrophobic side chains such as valine or isoleucine in
positions 45 and 46, but also aromatic residues. These AcrB binders all contain a tryptophan in
position 48, suggesting an important role for the formation of the binding interface. In positions
56 and 57 of DARPins #2-#8, almost exclusively aromatic amino acids have been selected for. In
the second internal repeat, a serine or threonine followed by leucine is found in almost all cases
in the β-turn region. The β-turn region of the third internal repeat frequently contains asparagine
or histidine in positions 111 or 112. Arginines are found in positions 122 or 123 of DARPins
#1, #2, #5-#8. We conclude that DARPins #2-#8 bind to the same epitope as DARPin#1.
In contrast, DARPin#9 contains basic residues in randomized positions 48, 56 and 57 in
place of aromatic residues. In fact, this binder differs from DARPin#1 in all randomized po-
sitions and also contains framework mutations. An interesting feature is a cysteine at position
122, which was not intended in the library design and musthave evolved during PCR amplifi-
cation between the selection cycles. Although we propose that the binding site overlaps based
on competition ELISA studies, we suggest that DARPin#9 binds AcrB in a different orientation
because it does not share any of the features that determine DARPin#1-like binding to AcrB.
In DARPins #6-#8, an interesting framework mutation occurred: the proline initiating helix 1
in the second internal repeat is replaced by leucine. We expect this mutation to have an effect on
the relative position of the helices [26].
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helix 1 helix 2 β-turn helix 1 helix 2
o^^o^o^o^o^o^o^o^o^o^o^o^ o^^ o^ o^o^o^o^o^o^o^ o^^ o^ o^o^o^o^o^ o^^ o^ o^o^o^o^o^o^o^
10. 20. 30. 40. 50. 60. 70.
N3C MRGSHHHHHHGSDLGKKLLEAARAGQDDEVRILMANGADVNAXDXXGXTPLHLAAXXGHLEIVEVLLKXG 70
DARPin#1 ........................R.................A.VV.W.......YW...........N. 70
DARPin#2 ..........................................R.FT.W.......HF...........N. 70
DARPin#3 ..........................................S.HV.W.......YF...........N. 70
DARPin#4 ..........................................F.FT.W.......YF......V....Y. 70
DARPin#5 ..........................................S.II.W.......NFD..........Y. 70
DARPin#6 ..........................................R.II.W.......YF...........H. 70
DARPin#7 ..........................................R.II.W.....V.YF...........H. 70
DARPin#8 ..........................................K.VI.W.......YF...........Y. 70
DARPin#9 ..........................................N.YS.K.......RR...........H. 70︸ ︷︷ ︸︸ ︷︷ ︸
N-Cap Repeat 1
β-turn helix 1 helix 2 β-turn helix 1 helix 2
o^^o^o^o^o^o^o^ o^^ o^ o^o^o^o^o^o^o^ o^^ o^ o^o^o^o^o^ o^^ o^ o^o^o^o^o^o^o^
80. 90. 100. 110. 120. 130. 140.
N3C ADVNAXDXXGXTPLHLAAXXGHLEIVEVLLKXGADVNAXDXXGXTPLHLAAXXGHLEIVEVLLKXGADVN 140
DARPin#1 .....Y.TL.S.......HF...........N......K.DN.I.......NR...........Y..... 140
DARPin#2 .....K.SL.V.......RR...........N......S.SH.F.......KR...........N..... 140
DARPin#3 .....D.SL.T.......DR....V......N......N.HN.F.......NI...........H..... 140
DARPin#4 .....T.TI.Y.......QK...........N......N.HN.F.......NI...........Y.V... 140
DARPin#5 .....M.TL.W.......WN...........Y......F.DA.T.......RR...........H..... 140
DARPin#6 .....E.TL.S.L.....HT...........H......M.SN.H.......RL...........Y..... 140
DARPin#7 .....E.TL.S.L.....HT...........H......M.SN.H.......RL...........Y..... 140
DARPin#8 V....E.TL.S.L.....HT...........H......M.SN.H.......RL...........Y..... 140
DARPin#9 .....I.NWRY.......YW...........H......L.KI.N.......DC...........H..... 140︸ ︷︷ ︸︸ ︷︷ ︸︸ ︷︷ ︸
Repeat 1 Repeat 2 Repeat 3
helix 1 helix 2
o^^o^o^o^o^o^o^ o^^ o^ o^o^o^o^o^
150. 160.
N3C AQDKFGKTAFDISIDNGNEDLAEILQKLN 169
DARPin#1 ..............N.............. 169
DARPin#2 ............................. 169
DARPin#3 .................S........... 169
DARPin#4 ............................. 169
DARPin#5 ............................. 169
DARPin#6 ............................. 169
DARPin#7 T............................ 169
DARPin#8 ............................. 169
DARPin#9 ............................. 169︸︷︷︸︸ ︷︷ ︸
Repeat 3 C-Cap
Figure 4.3: Alignment of amino acid sequences of DARPin binders to AcrB. Secondary structure
elements are indicated on top. Randomized positions are in a red frame. The alignment was
prepared using Texshade [27].
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4.3.2 Structures of AcrB-DARPin complexes
Overall binding mode
In addition to the previously known structure of AcrB with DARPin#1 (PDB ID 2J8S [16]),
we solved the structures of AcrB in complex with DARPin#2 and DARPin#3 at a resolution of
2.70 Å or 3.34 Å, respectively. The AcrB-DARPin complexes crystallized in 8-10 % PEG4000,
50 mM ADA pH 6.5 and 200 mM (NH4)2SO4. This condition had previously been optimized
for the AcrB-DARPin#1 complex. Other AcrB-DARPin complexes did not crystallize in this
condition. Statistics of processing and refinement are summarized in Table 4.1. The data could
be processed in the same space group, P212121, with similar unit cell parameters. However,
in the AcrB-DARPin#3 structure, the c-axis is more than 10 Å longer than in the other two
structures.
Two DARPins are bound to the AcrB trimer in all cases (Figure 4.4 A). The binders interact
with the DC subdomain which is part of the TolC docking domain of AcrB, located at the tip of
the periplasmic part of the transporter. The DC subdomain contains a 4-stranded beta-sheet and
the epitope is mainly formed by strand 802-811 on the surface of AcrB.
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Table 4.1: Data collection and refinement statistics.
Data collection AcrB-DARPin#1 AcrB-DARPin#2 AcrB-DARPin#3
PDB ID 2J8S [16] 3NOC 3NOG
Space group P212121 P212121 P212121
Unit cell parameters (Å) a = 146.2 a = 146.0 a = 145.4
b = 157.4 b = 158.7 b = 158.0
c = 246.0 c = 244.5 c = 258.6
Resolution (Å) 35.00-2.54 50.00-2.70 50.00-3.34
(highest shell) (2.70-2.54) (3.00-2.70) (3.60-3.34)
No. of unique reflections 177557 154197 86818
Redundancy 9.1 4.5 6.6
Completeness (%) 95.0 (79.0) 99.6 (99.8) 99.8 (99.7)
Rmerge 0.081 (0.321) 0.116 (0.365) 0.128 (0.363)
I/σ(I) 20.75 (6.1) 13.71 (4.02) 14.98 (3.9)
Refinement
Resolution (Å) 25.00-2.54 50.00-2.70 50.00-3.34
Number of reflections 177557 154197 86818
R (Rfree) 22.9 (27.0) 24.2 (26.8) 25.7 (30.7)
No. of waters 350 438 0
Mean B factors (2)
AcrB 42.3 60.4 76.1
DARPin (chain D) 42.2 66.1 89.5
DARPin (chain E) 54.2 101.2 161.0
RMS deviations
- bond lengths (Å) 0.008 0.008 0.014
- bond angles (degrees) 1.3 0.8 1.5
Ramachandran statistics
- allowed (No. of residues) 92.04 % (3144) 97.2 % (3279) 93.96 % (3160)
- generously allowed 5.59 % (191) 2.79 % (94) 5.86 % (197)
- disallowed 2.37 % (81) 0.03 % (1) 0.18 % (6)
82 CHAPTER 4. DARPIN BINDERS TO ACRB
When comparing the overall structure with the AcrB-DARPin#1 complex, the RMSD value
is 0.490 ± 0.289 Å for the AcrB-DARPin#2 complex and 1.540 ± 0.571 Å for the AcrB-
DARPin#3 complex. The crystal-contact mediating DARPin, bound to subunit B of AcrB, is
in the same position as in the other two structures, but the DARPin bound to subunit A is shifted
due to a change in the conformation of AcrB. This becomes evident when we superimpose
the transmembrane region of the AcrB-DARPin#3 complex with the corresponding region in
AcrB-DARPin#1. A small outward shift of transmembrane helices 2, 7, 9 and 12 is observed
in subunit A (Figure 4.4B). Since these transmembrane helices connect to the periplasmic part
of the molecule, this causes a rigid-body outward movement of the periplasmic domains of this
subunit and the neighboring chain C, explaining the substantial RMS deviation (Figure 4.4C,D).
Subunit A is involved in a crystal contact with subunit C via their periplasmic domains (Figure
4.5), which leads to the 10 Å difference in the length of one unit cell edge described above (Ta-
ble 4.1). This difference in the conformation of subunit A of AcrB in complex with DARPin#3
represents a subconformation of the access form of the protomer and illustrates the potential of
AcrB to adopt different conformations necessary for its function.
Figure 4.4: Comparison of crystal structures of AcrB-DARPin complexes. (A) AcrB-DARPin
structure overview: AcrB subunits (gray) and DARPin binders (orange) are shown in cartoon
representation viewed along the membrane plane. In subunit B, subdomains PN1 (light green),
PN2 (dark green), PC1 (rose), PC2 (blue), DN (yellow) and DC (red) are labeled in the respective
color. (B), (C), (D) Differences in the three DARPin AcrB complex. The transmembrane do-
main of AcrB-DARPin#3 was superimposed with the corresponding region in AcrB-DARPin#1.
The transmembrane domain (B), the porter domain (C) and the docking domain with bound
DARPins (D) are shown in stereo viewed from the periplasmic side (90ž rotation of (A) as in-
dicated). The yellow molecule represents the AcrB-DARPin#1 complex and AcrB-DARPin#3
is shown in blue. Transmembrane helices TM2, TM7, TM9 and TM12 that are affected by the
conformational rearrangement in the AcrB-DARPin#3 crystal are labeled.
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Resolution resulting from crystal packing
Even though the molecules are arranged in a very similar manner in all three structures of the
complex, the resolution that could be obtained is quite different comparing the three DARPins:
AcrB in complex with DARPin#1 was refined to 2.54 Å, with DARPin#2 to 2.70 Å, and the
AcrB-DARPin#3 complex could only be refined to 3.34 Å. A closer look at the crystal contact
reveals that this DARPin cannot form the crystal contact equally well as DARPin#1 or #2 (Table
4.2, Figure 4.6). A slight difference in angle reduces the number of hydrogen bonds to 4 instead
of 7 and the buried surface area from 444.4 Å2 to 409.8 Å2. This is a consequence of the different
conformation of AcrB in complex with DARPin#3 as described above, resulting in modified cell
parameters.
Figure 4.5: The unit cells of AcrB-DARPin crystals are drawn with a common origin. The unit
cell content of AcrB-DARPin#1 crystals shown in colors (chain A, green; chain B, blue; chain C,
yellow; chain D and chain E (DARPins), red; unit cell edges, red) is compared with the packing
of AcrB-DARPin#3 (white, unit cell edges, black). The outward movement of the periplasmic
part of chain A in the AcrB-DARPin#3 complex affects the crystal contact with chain C and
causes a shift of the symmetry-related molecules indicated by black arrows. As a consequence,
the c-edge is 12 Ålonger in crystals of AcrB-DARPin#3 as compared to AcrB-DARPin#1.
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Figure 4.6: Close-up on the DARPin mediated crystal contact (DARPin#1, yellow; DARPin#2,
green; DARPin#3, blue; AcrB residues, gray). (A) The DARPin viewed from the symmetry
mate is drawn in cartoon representation. Residues involved in a hydrogen bond are shown as
sticks. Hydrogen bonds are represented by red dashed lines. Stereo views of the close-up on
DARPin#1 (B), DARPin#2 (C), DARPin#3 (D) with a 2Fo-Fc electron density map contoured
at 1 sigma around residues involved in a hydrogen bond depicted as a gray mesh. The 2Fo-Fc
maps were calculated in PHENIX [28].
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Table 4.2: Hydrogen bonds or salt bridges in the DARPin-mediated crystal contact with the
cytoplasmic loops of AcrB subunit B.
AcrB DARPin#1 (Å) DARPin#2 (Å) DARPin#3 (Å)
Arg 536 (O) Asn 41 (ND2) 3.3 Asn 41 (ND2) 3.7
Arg 536 (NE) Gly 70 (O) 3.0 Gly 70 (O) 2.6
Arg 536 (NH2 Gly 70 (O) 2.8 Ala 71 (O) 3.4
Gly 957 (O) Arg 31 (NH1) 3.4
Leu 960 (N) Met 34 (O) 3.1 Met 34 (O) 2.8 Met 34 (O) 3.0
Glu 962 (OE2) Asn 69 (ND2) 3.8
Glu 962 (N) Asn 69 (OD1) 2.9 Asn 69 (OD1) 3.6 Asn 69 (OD1) 2.8
Glu 962 (OE1,
OE2)
Lys 68 (NZ) 3.7
AcrB-DARPin interface
The three structures of AcrB in complex with three different DARPins allow the direct compar-
ison of the interaction interface.
The buried surface area of the crystal-contact mediating DARPin (chain D) with AcrB is
relatively large with 1163.7 Å22 for the AcrB-DARPin#1 complex, 903.3 Å2 for the AcrB-
DARPin#2 complex and 1051.7 Å2 for the AcrB-DARPin#3 complex. We have performed a
computational alanine scan [29] to identify residues that are important for DARPin binding to
AcrB. On the AcrB surface, tryptophan 809 and tyrosine 811 were found to be the only residues
which are crucial for the interaction. These residues form a hydrophobic core with the ran-
domized positions of the first internal repeat. Key residues on the DARPin side are tryptophan
48, tryptophan or phenylalanine 57, and a small side chain in position 46 that can be valine,
isoleucine or threonine. In addition, framework residues contribute to the hydrophobic interac-
tions at positions 53, 77, and 145. The variation in the randomized positions leads to differences
in the DARPin interaction surface, resulting in a significantly lower shape complementarity of
0.477 for DARPin#3 as compared to 0.643 for DARPin#1 or 0.684 for DARPin#2. The latter
two values are in the range typically observed for antibody-antigen interactions [30].
The polar interactions between AcrB and the respective DARPin are summarized in Figure
4.7 (see also Tables 4.3/4.4). Equivalent hydrogen bonds in the core of the interface are fre-
quently observed in all three structures: For example, tryptophan 809 forms a hydrogen bond
via the hydroxyl group of serine or threonine 78. Also the polar interaction of asparagine or
histidine in position 112 (in DARPin#3 also histidine 111) is well-conserved. Salt bridges seem
to be quite exchangeable.
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Figure 4.7: Stereo view of the AcrB-DARPin binding interface. The DARPins surface is shown
in light gray. Residues involved in the interaction are drawn as sticks. DARPin residues in
randomized positions are colored yellow (A, DARPin#1), green (B, DARPin#2) or blue (C,
DARPin#3), and framework residues are orange. Relevant AcrB residues are shown in gray.
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Table 4.3: Hydrogen bonding (salt bridges) between chain D of DARPin#1-#3 and AcrB.
AcrB DARPin#1 (Å) DARPin#2 (Å) DARPin#3 (Å)
Subunit A
Lys 248 (NZ) Asn 156 (OD1) 3.0
Arg 263 (NH2) Asn 155 (O) 2.7 Asn 156 (O) 3.4 Asp 155 (O) 3.8
Subunit B
Ala 580 (O) His 45 (NE2) 3.1
Lys 659 (NZ) Asp 13 (OD2) 3.23
Asp 660 (OD1) Lys 16 (NZ) 2.4
Glu 693 (OE2) Arg 90 (NH1) 3.3 Arg 90 (NH1) 2.6
Asp 723 (O) Arg 23 (NH1) 3.2
Glu 734 (OE2) Lys 147 (NZ) 3.7 Lys 147 (NZ) 3.6 Lys 147 (NZ) 4.0
Ser 802 (O) Lys 144 (NZ) 2.6 Lys 144 (NZ) 3.1 Lys 144 (NZ) 3.1
Ser 805 (O) Lys 144 (NZ) 3.0 Lys 144 (NZ) 2.4 Lys 144 (NZ) 3.4
Ser 807 (O) Asn 112 (ND2) 2.7 His 112 (NE2) 3.2 His 111 (NE2) 3.2
Ser 807 (O) Asn 112 (ND2) 2.5
Ser 807 (N) Asn 112 (OD1) 3.3 Asn 112 (OD1) 3.2
Ser 807 (OH) His 112 (NE2) 2.83
Arg 808 (NH1) Asp89 (OD2) 3.4
Trp 809 (NE1) Ser 78 (OH) 2.9 Ser 78 (OH) 3.2
Tyr 811 (OH) Asp 44 (OD2) 3.1
Tyr 811 (N) Tyr 56 (OH) 3.0 Tyr 56 (OH) 3.6
Buried surface
area (Å2)
1163.6 855.8 1037.5
Shape comple-
mentarity
0.643 0.684 0.477
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Table 4.4: Hydrogen bonding (salt bridges) between chain E of DARPin#1-#3 and AcrB.
AcrB DARPin#1 (Å) DARPin#2 (Å) DARPin#3 (Å)
Subunit C
Arg 259 (NZ) Asp 155 (O) 3.8
Lys 248 (NZ) Asn 156 (O) 3.0
Arg 263 (NH1) Asn 155 (O) 2.6 Asn 156 (O) 3.6
Arg 263 (NH2) Ile 154 (O) 3.2 Ile 154 (O) 3.8 Asn 156 (O) 3.4
Subunit A
Glu 693 (OE2) Arg 90 (NH2) 2.7
Asp 723 (O) Arg 23 (NH1) 3.1 Arg 23 (NH1) 3.3
Glu 734 (OE2) Lys 147 (NZ) 2.7
Ser 802 (O) Lys 144 (NZ) 2.6 Lys 144 (NZ) 2.4
Ser 805 (O) Lys 144 (NZ) 3.0 Lys 144 (NZ) 2.7
Ser 807 (O) Asn 112 (ND2) 2.6 His 112 (NE2) 3.1 Asn 112 (ND2) 3.2
Trp 809 (NE1) Thr 78 (OG1) 2.9 Ser 78 (OH) 3.1 Ser 78 (OH) 2.9
Tyr 811 (N) Tyr 56 (OH) 3.0
Buried surface
area (Å2)
993.0 901.3 678.4
Shape comple-
mentarity
0.655 0.591 0.385
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In order to understand what makes this epitope so attractive for DARPin binding, we looked
at the surface of AcrB (Figure 4.8). Tryptophan 809 and tyrosine 811 are well-accessible for
protein-protein interaction, providing a hydrophobic patch and as well as a hydrogen bond ac-
ceptor. The periplasmic part of the transporter does not contain other similarly exposed trypto-
phan residues. A few tryptophans are found at the cytoplasmic end of the transmembrane helices.
They are probably shielded by the lipid bilayer or the detergent micelle. The presented struc-
tures show DARPin binding to subunit A (access/loose) and subunit B (binding/tight), but not
to subunit C (extrusion/open) despite the presence of the same hot-spot binding site. However,
DARPin binding is not compatible with the conformational rearrangements in this protomer
because of a steric clash with a helical portion of subdomain PC2 (Figure 4.9).
Trp 811
Tyr 811
Figure 4.8: Surface representation of AcrB in different shades of gray. Residues interacting with
DARPin binder DARPin#1 are colored in yellow. All tryptophan residues are shown in blue
tyrosines are cyan. The binding site for DARPin#1 contains a well-accessible tryptophan with a
neighboring tyrosine.
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steric clash
DARPin
PC2 PC1
DC
DN
PN1
PN2
binding / tight conformation       extrusion / open conformation
Figure 4.9: Cartoon representation of the periplasmic part of AcrB in the binding / tight confor-
mation (left) or the extrusion / open conformation (right) in the same orientation. The subunits
are labeled in the respective color. The DARPin is depicted in orange. A steric clash with PC2
subdomain prevents DARPin binding to the extrusion / open conformation of the AcrB protomer.
4.3.3 Biophysical characterization of the DARPin-AcrB interaction
Affinity
The affinity of DARPins #1-#9 to their target was determined using Surface Plasmon Resonance
(BIAcore). The kinetic parameters obtained are summarized in Table 4.5. All dissociation con-
stants are in the medium to low nanomolar range with values between 1.5 and 89 nM. Binding is
characterized by relatively fast off-rates. DARPin#2 shows the highest affinity to AcrB, combin-
ing the fastest on-rate with the slowest off-rate. Despite a less optimal shape complementarity of
the AcrB-DARPin#3 interaction, this binder displays a high affinity to AcrB with a dissociation
constant of 22.4 nM. The dissociation constants of DARPin#6-#8 differ significantly with values
of 7.6, 61.3 and 89.3 nM, even though the sequence of these DARPins only deviates in single
framework residues (Figure 4.3). The randomized positions are identical. This exemplifies the
importance of the exact spatial arrangement of the randomized patch by the scaffold structure.
We conclude that these substitutions destabilize the interaction and might have been introduced
at a later stage of the selection process.
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Table 4.5: Kinetic parameters of DARPin binding to AcrB determined by surface plasmon res-
onance.
DARPin kon [M−1s−1] koff [s−1] KD [nM] Rmax [RU] Chi2 [RU2]
DARPin#1 8.7 · 105 2.4 · 10−2 28.0
DARPin#2 6.0 · 106 9.0 · 10−3 1.5 25.6 0.441
DARPin#3 6.5 · 105 1.5 · 10−2 22.4 25.2 0.350
DARPin#4 2.0 · 106 3.7 · 10−2 18.7 22.7 0.301
DARPin#5 2.0 · 106 6.4 · 10−2 3.2 24.9 0.206
DARPin#6 3.7 · 106 2.8 · 10−2 7.6 26.6 0.214
DARPin#7 1.9 · 105 1.2 · 10−2 61.4 18.6 0.247
DARPin#8 1.6 · 105 1.4 · 10−2 89.3 14.0 0.426
Stoichiometry
The previously published crystal structure of the AcrB-DARPin complex [16] shows an asym-
metric conformation of AcrB with DARPins binding to two of the three chains of the trimer. We
investigated the stoichiometry of AcrB in complex with the other binders in solution. To this
end, we used gel filtration to isolate the complex and quantified each component using a protein
capillary electrophoresis chip.
Not all DARPins bind AcrB with the same stoichiometry (Table 4.6). In agreement with
the crystal structures, two molecules of DARPin#1, #2 or #3 form a complex with the AcrB
trimer. In contrast, we find one binder for DARPins #4, #5 and #9, while DARPin#6 and #7
form a complex composed of three DARPins per AcrB trimer. Only AcrB-DARPin complexes
with two binders could be crystallized in the same crystal form which requires the crystal-contact
mediating DARPin to be bound to subunit B (binding/tight conformation) of AcrB. We conclude
that only this stoichiometry is compatible with lattice formation in this particular crystal form.
If only one binder is present, it will likely interact with subunit C, which is in a conformation
that differs the most in the asymmetric structures determined so far. Binders to all three subunits
of AcrB might stabilize a more symmetric conformation of the transporter. This analysis again
illustrates the potential of ribosome display selection of binders, allowing to obtain information
regarding different functional states of a target protein.
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Table 4.6: Specificity of DARPin binders for AcrB.
DARPin Stoichiometry Specificity for AcrB
(DARPins/AcrB trimer) AcrB AcrD AcrF MexB
DARPin#1 2 +++ - - -
DARPin#2 2 +++ - + -
DARPin#3 2 +++ - + -
DARPin#4 1 +++ - - -
DARPin#5 1 +++ - + -
DARPin#6 3 +++ - + -
DARPin#7 3 +++ - - -
DARPin#8 n.d. +++ - - -
DARPin#9 1 +++ - - -
controls
α-AcrF - - +++ -
α-MexB - - - +++
Specificity
We further investigated the binding of DARPins to proteins homologous to AcrB, namely AcrD
(identity 66 %, similarity 80 %) and AcrF (identity 77 %, similarity 88 %) from Escherichia coli
as well as MexB from Pseudomonas aeruginosa (identity 69 %, similarity 83 %). The crystal
structure of AcrB in complex with DARPin#1 revealed a number of residues conserved in all
four RND transporters (Figure 4.10) that interact with the bound DARPin. The results of the
specificity analysis are summarized in Table 4.5. First, we used a streptavidin alkaline phos-
phatase conjugate to detect binding of chemically biotinylated RND transporters to immobilized
DARPins by ELISA. Binding of DARPin#2, #3, #5 and #6 to AcrF, but not AcrD or MexB,
could be detected (Figure 4.11A), while DARPin#1, #4, #7, #8 and #9 were specific for AcrB.
We used DARPins raised against AcrF and MexB as a control (Sennhauser, unpublished). These
binders were very specific for their respective target.
In order to compare the background interaction to binding by AcrB, we compared the sur-
face plasmon resonance signal (Figure 4.11B). The results agree well as background binding to
AcrF was observed for the listed DARPins. The cross-specific binders are among the DARPins
that show the highest affinity for AcrB. However, the signal from interaction with AcrF is
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710. 720. 730. 740. 750.
sp_P31224_ACRB QLLAEAAKHPDMLTSVRPNGLEDTPQFKIDIDQEKAQALGVSINDINTTL 750
sp_P24177_ACRD .......EN..E..R..H...D.S..LQID...R.......AID...D.. 748
sp_P24181_ACRF ...GM...H.AS.VS.........A...LEV...........LS...Q.I 749
sp_P52002_MEXB KF.M....N..A.QR.....MS.E..Y.LE..D...S.....LA...S.V 749
760. 770. 780. 790. 800.
sp_P31224_ACRB GAAWGGSYVNDFIDRGRVKKVYVMSEAKYRMLPDDIGDWYVRAADGQMVP 800
sp_P24177_ACRD Q....S......M............A.P........NL.....K..G... 798
sp_P24181_ACRF ...L.GT.............L....D..F....E.VD.L...S.N..... 799
sp_P52002_MEXB .I...S.............R..L.GRPDA..N...LS......DK..... 799
810. 820. 830. 840. 850.
sp_P31224_ACRB FSAFSSSRWEYGSPRLERYNGLPSMEILGQAAPGKSTGEAMELMEQLASK 850
sp_P24177_ACRD ..........T..........YSAV..V......V.T.T..DI..S.VKQ 848
sp_P24181_ACRF ....T..H.V.............S...Q......T.S........N.ASK 849
sp_P52002_MEXB .N....GK......K......V.A......P...L.S.....AV.EIVKQ 849
Figure 4.10: Alignment of RND transporters AcrD, AcrF and MexB with AcrB. Residues of
AcrB interacting with DARPin#1 and their corresponding residues in the other proteins are
highlighted in yellow. The alignment was prepared using Texshade [27]
much lower than for the interaction of DARPin DARPins with AcrB suggesting much lower
affinity constants. In agreement with the ELISA study, no interaction could be seen between
DARPin DARPins and AcrD or MexB. Interestingly, AcrF is less conserved (3 substitutions) in
the residues that are involved in binding to the DARPin in the DARPin#1-AcrB complex than
AcrD (only 1 substitution) (Figure 4.10). However, in terms of overall homology, AcrF is closest
to AcrB of all homologues tested, which seems to cause cross-reactivity with AcrB binders.
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Figure 4.11: Specificity of DARPins for AcrB: (A) ELISA detecting binding of DARPins to
AcrB, AcrD, AcrF or MexB (B) Surface plasmon resonance signals of DARPins #1-#3 and
α-MexB with AcrB, AcrD, AcrF and MexB.
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4.4 Discussion
4.4.1 Molecular recognition and evolutionary protein design
The generation of protein binders by various methods of evolutionary protein design is a power-
ful tool in modern molecular biology. In addition to antibodies and fragments thereof in diverse
formats, alternative scaffolds have been developed to overcome the limitations of antibodies. In
order to improve libraries for binder selection, it is important to understand the factors governing
molecular recognition. Likewise, the study of synthetic binding interfaces helps us understand
both natural and designed protein-protein interactions [31]. In this publication, we present the
first structural analysis of three DARPins binding to the same epitope. In addition to the crystal
structures of AcrB-DARPin complexes which allow the detailed analysis of the plasticity of the
interaction, the DARPins were biophysically characterized.
The analysis of a phage display library of human growth hormone (hGH) binding to its re-
ceptor is the most comprehensive mutational analysis of a protein-protein interface to date [32].
Analyzing a sequence database, the authors found that most residues are tolerant to substitution,
and only few residues in a hot-spot area are essential for binding. Rather than probing the adapt-
ability of a naturally evolved interface, our study analyzes a pool of designed proteins selected
for AcrB binding. The size difference suggests that there are many possibilities for the small
DARPins to interact with the target protein. Further experiments were therefore necessary to
distinguish between sequence diversity resulting from alternative binding sites or low selection
pressure on certain positions that are not involved in binding.
4.4.2 Dominant epitope
Our pool of DARPin binders from a ribosome display selection contains predominantly binders
to overlapping epitopes on AcrB. The binding site is mainly formed by one sheet of a beta
strand containing three serines followed by a tyrosine. These side chains are overrepresented
in the complementarity determining regions of antibodies [33]. Phage display libraries with
a minimalist amino acid composition, allowing only tyrosine, alanine, aspartate and serine in
the paratope, have been successfully used to select high-affinity binders to protein targets [34].
Further limitation to tyrosine and serine showed that a binary code, with only these two residues
forming the interaction surface, is sufficient for specific molecular recognition, both in the case
of antibody-antigen interaction [35] and protein binding by a FN3 scaffold [36].
In addition to the serines and tyrosine, a neighboring tryptophan contributes to the forma-
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tion of a surface area that is apparently more attractive for protein-protein interactions than
others. The question arises whether or not there is a functional meaning to the existence of such
a hydrophobic patch on the periplasmic domain of AcrB. Although the current model of the
AcrAB-TolC complex [37] suggests that the DARPin binding site would not be involved in the
formation of the functional assembly [38], we propose that this area is part of the interaction
surface of AcrB and AcrA. However, further experimental evidence is needed to clarify this
issue.
If a more diverse pool is desired, performing selections to the target molecule in complex
with a dominant binder might be helpful. By this means, the shielding of the most attractive
epitope would allow the enrichment of alternative binders.
4.4.3 Plasticity of the interface
Structural information on three of the AcrB-DARPin complexes binding to the same epitope
puts us in the position to identify the residues crucial for binding. This information can then be
used to recognize redundant binders on the sequence level. In agreement with the hGH study,
we find that only conservative changes occur around the hydrophobic core of the DARPin-AcrB
interface. Intermolecular polar interactions certainly stabilize the interaction, but seem to be
rather exchangeable. The highest affinity DARPin forms fewer hydrogen bonds and salt bridges
than the other two binders, but exhibits the highest shape complementarity.
4.4.4 DARPins for the improvement of membrane protein crystal quality
Our study aimed at evaluating DARPins for the crystallization of membrane proteins. We ob-
serve different stoichiometries critically affecting crystallization of the respective AcrB-DARPin
complex. Crystals grew when two DARPins formed a complex with the AcrB trimer, although
only one of the binders was involved in a crystal contact.
Interestingly, DARPins that bind substoichiometrically still compete for AcrB binding as
judged by ELISA. Even when only one or two DARPins bind to the homotrimer, leaving the
binding site on the other subunits unoccupied, mixed complexes do not seem to be formed. In
case of AcrB, the unoccupied binding sites are fixed in a conformation which is not favorable for
the interaction with a different DARPin. This observation supports the hypothesis that synthetic
binding proteins can trap a conformation of their target protein. Crystallization chaperones
thereby reduce conformational heterogeneity and facilitate nucleation of crystal growth.
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Even though the DARPins bind to the same site, the resolution obtained varied substantially.
Since the binders can only be selected for optimal interaction with the target protein rather
than formation of a crystalline lattice, it is important to consider screening of several DARPins
to achieve the best possible diffraction data. Although monodispersity at high concentrations
and reasonable affinity of the crystallization chaperone to the target are prerequisites for a suc-
cessful crystal growth, evaluation of biophysical properties of the complex in solution does not
guarantee optimal diffraction properties. Screening of several seemingly redundant binders is
therefore worthwhile to obtain the best-possible outcome. Construction of a focused library in
which residues determining the binding interface are kept constant would be a comprehensive
approach. Here, also optimization of surface residues potentially involved in crystal contacts
could be considered, for example by surface entropy reduction [39,40].
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4.5 Experimental procedures
4.5.1 Expression and purification
AcrB was expressed from a pET28 vector (Novagen) with a C-terminal His-tag and purified as
described previously [16] using buffer A (20 mM Tris pH 7.5, 150 mM NaCl, 0.03 % DDM).
The same procedure was used for the expression and purification of the homologs AcrD, AcrF
and MexB.
For enzymatic biotinylation [41], an expression vector for AcrB carrying a C-terminal His-
and avi-tag was constructed. A DNA fragment encoding the Avi tag sequence flanked by the re-
striction sites NheI and BamHI was formed by annealing the two oligonucleotides avitag_for (5’-
CAT GGG CGC TAG CGG TCT GAA CGA TAT CTT CGA AGC TCA GAA AAT CGA ATG
GCA CGA AGG ATC CTA AT-3’) and avitag_rev (5’- CTA GAT TAG GAT CCT TCG TGC
CAT TCG ATT TTC TGA GCT TCG AAG ATA TCG TTC AGA CCG CTA GCG CC -3’). The
fragment was ligated into the E. coli cloning vector pGEM using the NcoI and XbaI restriction
sites, yielding pGEM_Avi. The gene of acrB from Escherichia coli devoid of NcoI sites (Mu-
rakami and van Veen, unpublished) was amplified with the primers acrB_HisC_AviC_for (5’-
ATC CAT GGG GCC TAA TTT CTT TAT CGA TCG CCC G-3’) and acrB_HisC_AviC_rev (5’-
ATG CTA GCG TGA TGG TGA TGG TGA TGG TGA TGC TGC AGA TGA TGA TCG ACA
GTA TGG CTG TG-3’) and cloned via NcoI/NheI into pGEM_AviC yielding pGEMAcrBAviC.
The tagged acrB genes were sub-cloned into pBAD24 using the restriction sites NcoI and XbaI
resulting in pBADAcrBAviC, which was used for protein production.
Expression in Escherichia coli strain C43(DE3) was induced with 0.01 % D-arabinose at
OD600 = 0.5 for 4 h at 30 degrees. After purification via the C-terminal His-tag, AcrB-avi was
biotinylated over night at 4 degrees at a concentration of 10 µM with 50 µg of BirA in presence
of 5 mM ATP, 10 mM magnesium acetate and 1.2 fold excess of biotin in a total volume of
2500 µl of buffer A supplemented with 10 % glycerol. Excess biotin as well as BirA were
removed by gel filtration in buffer A-10 % glycerol on a Superdex 200 10/300 GL column
(Pharmacia).
Chemical biotinylation was performed after purification of RND transporters by IMAC using
the Tris-free buffers 10 mM, 50 mM and 200 mM imidazole/HCl pH 7.5, 150 mM NaCl, 10 %
glycerol and 0.03 % DDM. The protein was biotinylated with 1 mg/ml EZ-Link Sulfo-NHS-LC-
biotin (Pierce) for 30 min on ice. Excess biotin was removed by gel filtration in buffer A/10 %
glycerol on a Superdex 200 10/300 GL column (Pharmacia).
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4.5.2 Ribosome display
All binders used in this study originate from the third and fourth round of a ribosome display
selection described previously [16]. Briefly, binders to AcrB were selected from a N3C DARPin
library [5,10] after pre-panning with neutravidin, BSA and biotinylated maltose-binding protein
(MPB). The panning steps were performed at room temperature using buffer A.
4.5.3 ELISA
Crude extract ELISA with or without competition was performed as described by Huber et
al. [11] with some modifications, using TBS (50 mM Tris/HCl pH 7.4, 150 mM NaCl), TBS-
BSA (TBS with 0.5 % BSA), TBS-D (TBS containing 0.01 % DDM) or TBS-D-BSA (TBS-BSA
containing 0.03 % DDM) for binding and washing.
To prepare crude extract in a 96-well format, 1.2 ml per well of 2xYT medium containing
0.5 % glucose and 50 µg/ml ampicillin were inoculated with a single colony harboring the
expression plasmid pQE30-DARPin-(myc)5. The cultures were incubated at 37 degrees and
450 rpm. The next morning, 300 µl of the overnight culture was added to 900 µl of fresh 2xYT
with 100 µg/ml ampicillin. Expression was induced after 2 h at 37 degrees and 450 rpm with
IPTG at a final concentration of 0.25 mM. The cells were harvested after 3 h and lysed using
50 µl B-PERII (Pierce) for 10 min at room temperature. The lysate was diluted in 950 µl TBS
and stored at 4 degrees.
Immunoplates (Nunc) were coated with 100 µl per well of 5 ng/µl of Protein A in PBS,
pH 7.4, over night at 4 degrees. Each step was followed by washing three times with 300 µl
TBS or TBS-D after addition of the membrane protein. Incubation was at 4 degrees for 1 h
unless otherwise stated. The plates were blocked with 300 µl per well TBS-BSA for 1 h at room
temperature. Subsequently, 100 µl of α-myc IgG (Sigma, 1:2000 in TBS-BSA) were added to
each well and incubated for 2 h. DARPins were immobilized via their C-terminal myc-tag by
applying 100 µl of crude extract diluted 1:5 in TBS-BSA. Binding of chemically or enzymati-
cally biotinylated RND transporter (50 ng/µl in TBS-D-BSA, 100 µl/well) was detected using
a Streptavidin alkaline phosphatase conjugate (Roche, 1:5000 in TBS-D-BSA, 100 µl/well) and
the substrate di-sodium 4-nitrophenyl phosphate (Fluka). The absorbance at 405 nm was read
using a Genion plate reader. In case of competition ELISA, the biotinylated RND-transporter
was preincubated with a 20 fold excess of the competitor for 30 min at 4 degrees.
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4.5.4 Stoichiometry
We determined the stoichiometry of AcrB-DARPin complexes by quantifying the molar concen-
tration of each component by on-chip capillary electrophoresis using the Agilent Protein 80 or
230 Kit following the manufacturer’s protocols (Agilent Technologies). The samples were pre-
pared by gel filtration in buffer A/10 % glycerol to separate the complex from excess DARPin.
The protein concentration of samples used for standard curves was determined by amino acid
analysis. In order to compare the results from the two chips, we added 1/10 volume of MBP
from a 1 mg/ml stock to each sample. A standard curve was prepared loading AcrB samples at
different concentrations on the Agilent Protein 230 chip and we calculated the concentration of
AcrB in the complex, which was typically around 3 µM. The same sample was analyzed on the
Agilent Protein 80 chip, deducing the concentration of DARPin in the complex from a standard
curve. Subsequently, the stoichiometry was calculated from the concentration ratio.
4.5.5 Surface plasmon resonance (Biacore, Proteon)
Surface plasmon resonance measurements to study the binding kinetics of DARPins to AcrB
were carried out on a BIAcore T100 instrument at the Functional Genomics Center (FGCZ) of
the University and ETH Zurich. Buffer A was used for immobilization as well as during the
experiment. We immobilized 700 response units of chemically biotinylated AcrB in one flow
cell of a SA chip (BIAcore) at a flow rate of 10 µl/min, leaving the other flow cell uncoated for
referencing. DARPin analyte at various concentrations (0, 0.5, 1, 2, 4, 8, 16 and 32 nM or 0,
5, 10, 20, 40, 80, 160 and 320 nM) was injected with 180 s contact time and 600 s dissociation
time at a flow rate of 60 µl/min. The dissociation time was sufficient to regenerate the chip. The
data was analyzed using a kinetic fit with a 1:1 binding model after subtraction of the signal in
the uncoated reference cell.
For the specificity analysis, surface plasmon resonance was analyzed using a ProteOn XPR36
protein interaction array system (BioRAD) at the FGCZ. On a NLC sensor chip (BioRAD), 1500
to 2000 RU of chemically biotinylated AcrB, AcrD, AcrF or MexB were immobilized via the
interaction with neutravidin in ligand channels 1 to 4. The residual ligand channels were left
uncoated. DARPins at 0, 3, 9, 27, 81 and 243 nM or 0, 15, 45, 135, 405 and 1215 nM were used
for simultaneous analysis of the interaction in analyte channels 1 to 6. Binding kinetics were
followed during 180 s contact time and 600 s dissociation time at a flow rate of 60 µl/min. The
signal after double referencing using interspot regions and the blank analyte was analyzed qual-
itatively comparing the different RND transporters. For controls, DARPins specific for AcrF or
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MexB were used. These had been generated by ribosome display selection from a N2C library
using the protocol described previously [16].
4.5.6 Crystallization and structure determination
AcrB:DARPin complexes were crystallized by sitting drop vapour diffusion in 8-12 % PEG
4000, 50 mM ADA pH 6.5, 200 mM (NH4)2SO4 as described previously [16]. Data were col-
lected on a PILATUS detector (Dectra) at the Swiss Light Source beamline XS06DA of the
Paul Scherrer Institute (Villigen, Switzerland). XDS [42] was used for processing. The struc-
tures were solved by molecular replacement in PHASER [43] using the previously determined
AcrB-DARPin complex as a search model (PDB ID 2J8S [16]) and refined in PHENIX [28].
4.5.7 Computational analysis of structures
The Computational Interface Alanine Scanning server [29] was used to identify residues crucial
for DARPin binding to AcrB. The coordinate files for the structures of AcrB-DARPin complexes
were submitted to the PISA server [44] at the European Bioinformatics Institute to calculate the
buried surface area and analyze in detail the protein-protein interaction both in the DARPin-
AcrB binding site and crystal contacts. Shape complementarity values were obtained using the
program sc [30]. All figures of protein structures were prepared with Pymol [45].
4.5.8 Accession numbers
The atomic coordinates and structure factors have been deposited in the Protein Data Bank with
accession number 3NOC for the AcrB-DARPin#2 complex and 3NOG for AcrB-DARPin#3
complex.
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Appendix A
Materials
A.1 Cell lines and bacterial strains
Sf9 from Spodoptera frugiperda Invitrogen
Escherichia coli DH10BacTM F mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15
∆lacX74 recA1 endA1 araD139 ∆(ara
leu) 7697 galU galK λ− rpsL nupG/
pMON14272/pMON7124
Invitrogen
Escherichia coli XL1blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1
lac FŠ proAB lacIqZ∆M15 Tn10 Tetr
Stratagene
Escherichia coli BL21(DE3) F dcm ompT hsdS(rB mB) gal λ(DE3) [1]
Escherichia coli C43(DE3) F dcm ompT hsdSB(rB mB) gal lon λ(DE3) [2]
A.2 Oligonucleotides and plasmids
Oligonucleotides for the generation and analysis of Ntcp vectors and bacmids
BamHI-Ntcp 5’-CCA GGA TCC GAT GGA GGT GCA CAA CG-3’
Ntcp-HindIII 5’-CAC AAG CTT ATT ATC TAG AAT TTG CCA TCT
GAC CAG-3’
Xba-His-for 5’-CTA GAC ACC ACC ACC ACC ACC ACT AAT A-3’
Xba-His-rev 5’-AGC TTA TTA GTG GTG GTG GTG GTG GTG T-3’
Strep-for 5’-CTA GAT GGT CGC ACC CGC AAT TTG AAA AAT
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AAT A-3’
Strep-rev 5’-AGC TTA TTA TTT TTC AAA TTG CGG GTG CGA
CCA T-3’
FastBacf 5’-TAC TGT TTT CGT AAC AGT TTT G-3’
FastBacr 5’-CAT TTT ATG TTT CAG GTT CAG G-3’
M13-for 5’-GTT TTC CCA GTC ACG AC-3’
M13-rev 5’-CAG GAA ACA GCT ATG AC-3’
Oligonucleotides for the construction of expression vectors for extracellular do-
main of Oatp1a4
loop1a4-for1 5’-CCT CCA TGG AAT TCG TGG CAG GCT TAA C-3’
loop1a4-for2 5’-CCT CCA TGG AAT TCG CTG ACT GTA ACA C-3’
loop1a4-rev1 5’-CCT CTA GAA GCT TGG CAC AGT CAG GG-3’
loop1a4-rev2 5’-CCT CTA GAA GCT TAA TGC AGC TGC AAT TC-3’
loop1a4-rev1-stop 5’-GCA AGC TTT TAT TAC CCG GGG GCA CAG TCA GG-3’
loop1a4-rev2-stop 5’-GCA AGC TTT TAT TAC CCG GGA ATG CAG CTG CA-3’
Oligonucleotides for the modification and amplification of DARPins
EWT5 5’-TTC CTC CAT GGG TAT GAG AGG ATC GCA TCA CCA
TCA CCA TCA CGG ATC CGA CCT GGG-3’
WTC4 5’-TTT GGG AAG CTT TTG CAG GAT TTC AGC-3’
MTS46 5’-GCA TAA GCT TCA TTA GTT CAG TTT CTG CAG GAT
TTC AGC CAG-3’
Plasmids
pSPORT-Ntcp Stieger lab, University Hospital Zurich
pSPORT-Oatp1a4 Stieger lab, University Hospital Zurich
pET28-AcrB-His Gaby Sennhauser, University of Zurich [3]
pQE30 Qiagen
pFastBac Invitrogen
pET20b(+) Novagen
pMAL-c2E New England Biolabs
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pMAL-pm1 Peer Mittl, University of Zurich
pGEX-6P1 Amersham Biosciences
pETM80 Annett Dümmler, EMBL Heidelberg [4]
pETM82 Annett Dümmler, EMBL Heidelberg [4]
pETNus-1a Sattler lab, EMBL Heidelberg
pETTrx-1a Sattler lab, EMBL Heidelberg
pETGB1-1a Sattler lab, EMBL Heidelberg
pETMBP-1a Sattler lab, EMBL Heidelberg
A.3 Enzymes and antibodies
Enzymes for DNA modification
RNAse A Roche
BamHI New England Biolabs
HindIII New England Biolabs
T4 DNA ligase New England Biolabs
Taq polymerase New England Biolabs
Enzymes used during protein purification
DNAseI Roche
Tobacco Etch Virus (TEV) protease produced and purified in-house
Reagents for immunoassays
Protein A Sigma
Mouse α-myc IgG Sigma
K4 rabbit α-Ntcp polyclonal antibody provided by Stieger lab, Uni-
versity Hospital Zurich
Goat α-rabbit IgG horse radish peroxi-
dase (HRP) conjugate
Sigma
Streptavidin alkaline phosphatase (AP)
conjugate
Roche
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Disodium 4-nitrophenyl phosphate
(pNPP)
Fluka
ECl Kit GE Healthcare
A.4 Media and solutions for cloning and protein expression
Media and stock solutions for bacterial expression
LB 10 g/l bacto tryptone
5 g/l yeast extract
10 g/l NaCl
2xYT 16 g/l bacto tryptone
10 g/l yeast extract
5 g/l NaCl
Ampicillin 100 mg/ml stock
Kanamycin 50 mg/ml stock
Tetracyclin 15 mg/ml stock
Gentamycin 7 mg/ml stock
X-gal 100 mg/ml stock
IPTG 1 M stock
Insect cell culture media, solutions and reagents
Sf-900 II SFM Gibco
Grace’s Medium Gibco
Fetal Calf Serum (FCS) Gibco
Penicillin/Streptomycin Gibco
Cellfectin Invitrogen
Trypan blue Invitrogen
Thiazolyl Blue Tetrazolium Blue
(MTT)
Sigma
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A.5 Buffers and solutions
Buffers for the isolation of bacmid DNA
Solution I 15 mM Tris/HCl pH 8.0
(resuspension) 10 mM EDTA
100 µM RNAse A
filtered 0.2 µm
Solution II 0.2 N NaOH
(lysis) 1 % (w/v) SDS
filtered 0.2 µm
Solution III 3 M potassium acetate, pH 5.5
(neutralization) autoclaved
Buffers for the Ntcp transport assay in Sf9 cells
Sodium buffer 122 mM NaCl
10 mM MES pH 6.5
3 mM CaCl2
5 mM MgCl2
5 mM D-glucose
Choline buffer 122 mM choline chloride
10 mM MES pH 6.5
3 mM CaCl2
5 mM MgCl2
5 mM D-glucose
Hot solution 10 µM [3H]-taurocholate (2.5 µCi/ml in sodium
or choline buffer
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Buffers for membrane preparation from Sf9 cells expressing Ntcp
TMEP 50 mM Tris/HCl pH 7.0
50 mM mannitol
2 mM EGTA
Complete (Roche)
SMS 20 mM HEPES/Tris pH 7.5
250 mM sucrose
0.2 mM CaCl2
Buffers for the purification of the extracellular domain of Oatp1a4
Amylose lysis buffer 50 mM Tris/HCl pH 8.0
150 mM NaCl
1 mM DTT
0.1 mg/ml DNAse I
Amylose column running buffer 50 mM Tris/HCl pH 8.0
150 mM NaCl
Amylose column elution buffer 50 mM Tris/HCl pH 8.0
150 mM NaCl
10 mM D-maltose
Ni-NTA ysis buffer 50 mM Tris/HCl pH 8.0
150 mM NaCl
3 mM GSH
3 mM GSSG
10 mM imidazole
0.1 mg/ml DNAse I
Ni-NTA loading buffer 50 mM Tris/HCl pH 8.0
150 mM NaCl
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10 mM imidazole
Ni-NTA wash buffer Ni-NTA buffer with 20 mM imidazole
Ni-NTA elution buffer Ni-NTA buffer with 250 mM imidazole
TEV cleavage buffer 50 mM Tris/HCl pH 8.0
150 mM NaCl
3 mM GSH
0.3 mM GSSG
or 50 mM Tris/HCl pH 8.0
150 mM NaCl
1 mM DTT
Size exclusion buffer 50 mM Tris/HCl pH 8.0
150 mM NaCl
Buffers for the purification of AcrB
Master buffer (Buffer A) 20 mM Tris/HCl pH 7.5
150 mM NaCl
Lysis buffer (LB) 20 mM Tris/HCl pH 7.5
150 mM NaCl
0.1 mg/ml DNAseI
Complete
Solubilization buffer (SB) 20 mM Tris/HCl pH 7.5
150 mM NaCl
10 % (v/v) glycerol
10 mM imidazole
1 % DDM
Complete (EDTA-free)
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Binding buffer (BB) 20 mM Tris/HCl pH 7.5
150 mM NaCl
10 % (v/v) glycerol
10 mM imidazole
0.03 % DDM
Wash buffer (WB) BB with 50 mM imidazole
Elution buffer (EB) BB with 200 mM imidazole
Gel filtration buffer (GF) 20 mM Tris/HCl pH 7.5
150 mM NaCl
0.03 % DDM
HEPES buffer 10 mM HEPES/NaOH pH 7.5
50 mM NaCl
0.03 % DDM
Buffers for the purification of DARPins
Lysis buffer 50 mM Tris/HCl pH 7.5
400 mM NaCl
0.1 mg/ml DNAseI
Binding buffer 50 mM Tris/HCl pH 7.5
400 mM NaCl
20 mM imidazole
10 % (w/v) glycerol
Elution buffer 50 mM Tris/HCl pH 7.5
400 mM NaCl
250 mM imidazole
10 % (w/v) glycerol
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Buffers for SDS PAGE and Western Blot
Electrophoresis buffer (5x) 125 mM Tris
1 M glycine
5 g/l (w/v) SDS
high TBS 50 mM Tris/HCl pH 7.0
500 mM NaCl
high TBS-T TBS with 0.2 % Tween20
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Appendix B
Crystallization of other AcrB-DARPin
complexes
Further crystallization trials were carried out with AcrB-DARPin complexes. Figure B.1 and
Table B.1 summarize hits observed during the screening process. All crystals were tested at the
Swiss Light Source (Paul-Scherrer Institute, Villigen, Switzerland). Some crystals diffracted
to moderate resolution. Where the data was sufficient to determine the unit cell dimensions,
the processing statistics are listed in Table (insert Table). For the two cases where the structures
could be solved by molecular replacement with AcrB at low resolution, no density for a DARPin
binder was found.
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Figure B.1: Crystallization of AcrB in complex with DARPin#4, #5, #7, #8 and #9. The condi-
tions are listed in Table B.1.
Table B.1: Crystallization of AcrB-DARPin complexes. This table
summarizes the crystallization conditions and diffraction proper-
ties of the AcrB-DARPin crystals shown in Figure B.1.
Image Complex Condition Comments
1 AcrB-DARPin#4 15 % PEG400, 50 mM
glycine pH 9.4, 150 mM
NaCl
2 AcrB-DARPin#4 10 % PEG4000, 50 mM Na
cacodylate pH 5.5, 1 M NaCl
3 AcrB-DARPin#5 5 % PEG4000, 50 mM Na
cacodylate pH 5.5, 150 mM
magnesium acetate
diffracted to 20 Å
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4 AcrB-DARPin#5 5 % PEG4000, 50 mM Na
cacodylate pH 5.5, 175 mM
magnesium acetate
5 AcrB-DARPin#5 15 % PEG400, 50 mM ADA
pH 6.5, 50 mM magnesium
acetate
6 AcrB-DARPin#7 15 % PEG400, 50 mM Na ac-
etate pH 4.5, 50 mM magne-
sium acetate
diffracted to 7 Å
7 AcrB-DARPin#7 5 % PEG4000, 50 mM ADA
pH 6.5, 200 mM ammonium
sulfate
diffracted to 5 Å
8 AcrB-DARPin#7 10 % PEG4000, 50 mM ADA
pH 6.5, 200 mM ammonium
sulfate
9 AcrB-DARPin#8 5 % PEG4000, 50 mM ADA
pH 6.5, 1 M NaCl
10 AcrB-DARPin#8 5 % PEG4000, 50 mM Na ac-
etate pH 4.5, 150 mM NaCl
20 frames
11 AcrB-DARPin#8 12 % PEG4000, 100 mM
MES pH 6.5, 100 mM NaCl
12 AcrB-DARPin#9 30 % PEG400, 100 mM ADA
pH 6.5, 300 mM lithium sul-
fate, 2 mM dequalinium
diffracted to 8.5 Å
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